<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">96962</article-id><article-id pub-id-type="doi">10.7554/eLife.96962</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.96962.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Functional identification of soluble uric acid as an endogenous inhibitor of CD38</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Shijie</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7686-5049</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Arakawa</surname><given-names>Hiroshi</given-names></name><email>arakawa0403@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Shigeru</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shirasaka</surname><given-names>Yoshiyuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Higashida</surname><given-names>Haruhiro</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Tamai</surname><given-names>Ikumi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4388-083X</contrib-id><email>tamai@p.kanazawa-u.ac.jp</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j6c0d67</institution-id><institution>Faculty of Pharmaceutical Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University</institution></institution-wrap><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02j6c0d67</institution-id><institution>Research Center for Child Mental Development, Kanazawa University</institution></institution-wrap><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00msqp585</institution-id><institution>Division of Socio-Cognitive-Neuroscience, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui</institution></institution-wrap><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mori</surname><given-names>Marcelo A</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04wffgt70</institution-id><institution>State University of Campinas</institution></institution-wrap><country>Brazil</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>11</month><year>2024</year></pub-date><volume>13</volume><elocation-id>RP96962</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-02-23"><day>23</day><month>02</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-02-23"><day>23</day><month>02</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.06.03.543541"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-04-26"><day>26</day><month>04</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96962.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-30"><day>30</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.96962.2"/></event></pub-history><permissions><copyright-statement>© 2024, Wen et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Wen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-96962-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-96962-figures-v1.pdf"/><abstract><p>Excessive elevation or reduction of soluble uric acid (sUA) levels has been linked to some of pathological states, raising another subject that sUA at physiological levels may be essential for the maintenance of health. Yet, the fundamental physiological functions and molecular targets of sUA remain largely unknown. Using enzyme assays and in vitro and in vivo metabolic assays, we demonstrate that sUA directly inhibits the hydrolase and cyclase activities of CD38 via a reversible non-competitive mechanism, thereby limiting nicotinamide adenine dinucleotide (NAD<sup>+</sup>) degradation. CD38 inhibition is restricted to sUA in purine metabolism, and a structural comparison using methyl analogs of sUA such as caffeine metabolites shows that 1,3-dihydroimidazol-2-one is the main functional group. Moreover, sUA at physiological levels prevents crude lipopolysaccharide (cLPS)-induced systemic inflammation and monosodium urate (MSU) crystal-induced peritonitis in mice by interacting with CD38. Together, this study unveils an unexpected physiological role for sUA in controlling NAD<sup>+</sup> availability and innate immunity through CD38 inhibition, providing a new perspective on sUA homeostasis and purine metabolism.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>uric acid</kwd><kwd>CD38</kwd><kwd>nicotinamide adenine dinucleotide</kwd><kwd>inflammation</kwd><kwd>hyperuricemia</kwd><kwd>hypouricemia</kwd><kwd>MSU crystal</kwd><kwd>gout</kwd><kwd>metabolism</kwd><kwd>uricase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>KAKENHI [JP21H02641]</award-id><principal-award-recipient><name><surname>Tamai</surname><given-names>Ikumi</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>KAKENHI [JP23K18181]</award-id><principal-award-recipient><name><surname>Tamai</surname><given-names>Ikumi</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>KAKENHI [JP22K19372]</award-id><principal-award-recipient><name><surname>Arakawa</surname><given-names>Hiroshi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100020376</institution-id><institution>Gout and Uric Acid Foundation</institution></institution-wrap></funding-source><award-id>Research Grant 2022</award-id><principal-award-recipient><name><surname>Tamai</surname><given-names>Ikumi</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Soluble uric acid at physiological levels limits NAD<sup>+</sup> degradation and excessive inflammation by directly inhibiting CD38.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The evolutionary loss of uricase activity in humans and certain primates completely blocks the degradation of soluble uric acid (sUA), leading to higher physiological levels of sUA than in other mammals (<xref ref-type="bibr" rid="bib63">Oda et al., 2002</xref>; <xref ref-type="bibr" rid="bib78">Wu et al., 1992</xref>). Owing to renal reabsorption, sUA is strictly maintained in humans rather than being eliminated as a waste. It has been suggested that sUA functions as an abundant antioxidant (<xref ref-type="bibr" rid="bib26">Glantzounis et al., 2005</xref>) and is crucial to maintain blood pressure (<xref ref-type="bibr" rid="bib75">Watanabe et al., 2002</xref>). Although hyperuricemia may promote the precipitation of monosodium urate (MSU) crystal, an activator of the NLRP3 inflammasome (<xref ref-type="bibr" rid="bib56">Martinon et al., 2006</xref>), resulting in diseases such as gout (<xref ref-type="bibr" rid="bib19">Dehlin et al., 2020</xref>) and kidney stone disease (<xref ref-type="bibr" rid="bib34">Howles and Thakker, 2020</xref>), numerous studies have indicated the protective potential of sUA in neurodegenerative diseases (<xref ref-type="bibr" rid="bib40">Kutzing and Firestein, 2008</xref>; <xref ref-type="bibr" rid="bib51">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib68">Scott et al., 2002</xref>). In addition, abnormal reduction of sUA levels is clinically associated with the risk of various diseases (<xref ref-type="bibr" rid="bib13">Crawley et al., 2022</xref>; <xref ref-type="bibr" rid="bib40">Kutzing and Firestein, 2008</xref>), including cardiovascular diseases and kidney diseases. Intriguingly, rapid urate reduction in the initiation of therapy even increases gout flares in patients (<xref ref-type="bibr" rid="bib5">Becker et al., 2005</xref>). Depletion of sUA in uricase-transgenic mice shortens lifespan and promotes sterile inflammation induced by microbial molecules or pro-inflammatory particles (<xref ref-type="bibr" rid="bib39">Kono et al., 2010</xref>; <xref ref-type="bibr" rid="bib70">Shi, 2010</xref>). Thus, data supports that sUA provides a physiological defense against excessive inflammation, aging, and certain diseases (<xref ref-type="bibr" rid="bib3">Álvarez-Lario and Macarrón-Vicente, 2010</xref>; <xref ref-type="bibr" rid="bib4">Ames et al., 1981</xref>; <xref ref-type="bibr" rid="bib13">Crawley et al., 2022</xref>; <xref ref-type="bibr" rid="bib14">Cutler et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Kutzing and Firestein, 2008</xref>; <xref ref-type="bibr" rid="bib43">Lai et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Linnerz et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Wan et al., 2020</xref>; <xref ref-type="bibr" rid="bib77">Wen et al., 2024</xref>). However, the underlying molecular basis of sUA physiology remains poorly understood.</p><p>To gain insight into target-based physiological functions of sUA, our laboratory utilized magnetic bead-conjugated 8-oxoguanine (8-OG, an sUA analog; technically, sUA cannot be directly conjugated to the beads) and proteomic analysis to screen the potential candidates of sUA-binding proteins. We discovered several binding proteins of 8-OG (unpublished data), including CD38 that was verified by enzyme inhibition (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), which raised our interest in exploring the role of CD38 in sUA physiology. CD38 is mainly expressed in immune cells and has type II or type III membrane orientation, with the catalytic domain facing the outside or inside of cells (<xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>; <xref ref-type="bibr" rid="bib46">Lee and Zhao, 2019</xref>; <xref ref-type="bibr" rid="bib81">Zhao et al., 2012</xref>). It is also found in intracellular membranes or as intracellular and extracellular soluble forms (<xref ref-type="bibr" rid="bib11">Chini et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Funaro et al., 1996</xref>; <xref ref-type="bibr" rid="bib46">Lee and Zhao, 2019</xref>; <xref ref-type="bibr" rid="bib82">Zielinska et al., 2004</xref>). Functionally, CD38 serves as a hydrolase to degrade nicotinamide adenine dinucleotide (NAD<sup>+</sup>) (<xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>), an essential cofactor for various metabolic reactions that sustain life (<xref ref-type="bibr" rid="bib52">Luongo et al., 2020</xref>), as well as its precursor nicotinamide mononucleotide (NMN) (<xref ref-type="bibr" rid="bib12">Chini et al., 2020</xref>), thus regulating inflammation, aging, and various diseases (<xref ref-type="bibr" rid="bib11">Chini et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>). Its cyclase catalyzes the synthesis of cyclic ADP-ribose (cADPR) from NAD<sup>+</sup> to drive calcium mobilization (<xref ref-type="bibr" rid="bib45">Lee, 2001</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 1989</xref>), which is crucial for social behavior (<xref ref-type="bibr" rid="bib38">Jin et al., 2007</xref>) and neutrophil recruitment (<xref ref-type="bibr" rid="bib64">Partida-Sánchez et al., 2001</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Identification of soluble uric acid (sUA) as an endogenous inhibitor for CD38.</title><p>(<bold>A</bold>) Preliminary screening of 8-oxoguanine (8-OG) binding proteins by mass spectrum (MS)-based proteomics, and effect of 8-OG (50 μM) on CD38 activity (n=3 experiments/technical replicates). (<bold>B</bold>) Hydrolase and cyclase activities of recombinant human CD38 (hCD38) in the presence of sUA (0–500 μM), using nicotinamide 1, <italic>N</italic><sup>6</sup>-ethenoadenine dinucleotide (ε-NAD<sup>+</sup>), and nicotinamide guanine dinucleotide (NGD) as substrates, respectively (n=3 experiments/technical replicates). (<bold>C and D</bold>) Effect of different substrate concentrations on sUA inhibition of recombinant hCD38 hydrolase (<bold>C</bold>) and cyclase (<bold>D</bold>) activities (n=3 experiments/technical replicates). (<bold>E</bold>) Effect of different sUA concentrations (0–500 μM) on hydrolase and cyclase activities (FU/min/μg protein) in tissues from 8- to 12-week-old wild-type (WT) mice (n=3 experiments from 3 mice). (<bold>F and G</bold>) Reversibility of inhibition of recombinant hCD38 hydrolase (<bold>F</bold>) and cyclase (<bold>G</bold>) activities by sUA. After 30 min pre-incubation as indicated, samples were diluted 100-fold in reaction buffer with or without 500 μM sUA for enzyme assay (n=3–5 experiments/technical replicates). Data are mean ± s.d. (<bold>B–E</bold>) or mean ± s.e.m. (<bold>A</bold>, <bold>F</bold>, and <bold>G</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Soluble uric acid (sUA) inhibition of CD38 and reversibility in THP-1 and A549 cells.</title><p>(<bold>A</bold>) Hydrolase activity of THP-1 cells in the presence of sUA (0–500 μM) (n=3 experiments/technical replicates). (<bold>B</bold>) Effect of different ε-NAD<sup>+</sup> concentrations on sUA inhibition of hydrolase activity of THP-1 cells (n=3 experiments/technical replicates). (<bold>C and D</bold>) Reversibility of inhibition of hydrolase (A549 cells) (<bold>C</bold>) and cyclase (THP-1 cells) (<bold>D</bold>) by sUA (n=3 experiments/technical replicates). Data are mean ± s.d. (<bold>A and B</bold>) or mean ± s.e.m. (<bold>C and D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Endogenous soluble uric acid (sUA) concentrations in the final reaction buffer for enzyme assays.</title><p>sUA levels in initial homogenate or membrane fractions were measured, then the endogenous sUA concentrations in the final reaction buffer were calculated based on loading dilution (n=3 biologically independent samples). Data are mean ± s.e.m.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig1-figsupp2-v1.tif"/></fig></fig-group><p>Here, we demonstrate that sUA at physiological levels directly inhibits CD38 and consequently limits NAD<sup>+</sup> degradation and excessive inflammation, which defines, for the first time, the physiological functions of sUA via CD38. In addition, we confirm the unique effect of sUA on CD38 in purine metabolism and identify a structural feature for pharmacological inhibition of CD38.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>sUA is an endogenous, reversible, and non-competitive inhibitor of CD38</title><p>To clarify whether CD38 is a direct target for sUA, we investigated the effect of sUA on CD38 activity. We found that sUA directly inhibited the hydrolase and cyclase activities of human (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and murine (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) CD38 as a non-competitive inhibitor (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) with a K<sub>i</sub> in the micromolar range (57.1–93.3 μM), demonstrating its binding to the allosteric sites of CD38. sUA showed comparable inhibitory effects on hydrolase and cyclase, as indicated by similar K<sub>i</sub>. The physiological levels of sUA in humans (about 120–420 μM) (<xref ref-type="bibr" rid="bib15">Dalbeth et al., 2021</xref>; <xref ref-type="bibr" rid="bib41">Kuwabara et al., 2017</xref>) and in several mouse tissues (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) were higher than its K<sub>i</sub>, indicating that human CD38 and murine type III/intracellular CD38 are physiologically inhibited by sUA. The inhibitory effects were reversible (<xref ref-type="fig" rid="fig1">Figure 1F and G</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>), suggesting that sUA dynamically modulates CD38 activity. Interference from endogenous sUA was negligible when using tissues as an enzyme source, because the concentrations in the final reaction buffer were below 1 μM (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p></sec><sec id="s2-2"><title>CD38 inhibition is restricted to sUA in purine metabolism</title><p>Although the structure of sUA is similar to that of other purines, we confirmed its unique effect on CD38 in the major metabolic pathways of purines (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). sUA precursors (adenosine, guanosine, inosine, hypoxanthine, and xanthine) and the uricase-catalyzed metabolite (allantoin) hardly inhibited the hydrolase and cyclase activities of human (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>) and murine (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B and C</xref>) CD38. The tested purine concentrations were higher than their physiological levels (<xref ref-type="bibr" rid="bib7">Boulieu et al., 1983</xref>; <xref ref-type="bibr" rid="bib21">Dudzinska et al., 2010</xref>; <xref ref-type="bibr" rid="bib22">Eells and Spector, 1983</xref>; <xref ref-type="bibr" rid="bib72">Traut, 1994</xref>). Thus, CD38 inhibition is restricted to sUA, suggesting a specific functional group in sUA.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CD38 inhibition is restricted to soluble uric acid (sUA) in purine metabolism.</title><p>(<bold>A</bold>) Major pathways of purine metabolism. (<bold>B and C</bold>) Effect of sUA and its precursors and metabolite on hydrolase and cyclase activities of recombinant hCD38 (n=3 experiments/technical replicates for each ligand). (<bold>D</bold>) Effect of different analogs on hydrolase and cyclase activities (n=3 experiments/technical replicates). THP-1 cells were used to detect the effects of oxypurinol, caffeine, 1-methyluric acid (1-MU), and 1,3-dimethyluric acid (1,3-DMU) on hydrolase activity, recombinant hCD38 was used in the remaining detections. (<bold>E</bold>) Effect of uracil and 1,3-dihydroimidazol-2-one (1,3-DHI-2-one) on hydrolase and cyclase activities of recombinant hCD38 (n=3 experiments/technical replicates). (<bold>F</bold>) A structural comparison reveals the functional group for CD38 inhibition. The concentrations of all ligands are from 5 to 500 μM. Data are mean ± s.e.m.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Effect of soluble uric acid (sUA), sUA precursors, and metabolite, and other derivates on CD38 activity in cells and tissues.</title><p>(<bold>A–C</bold>) Effect of sUA and its precursors and metabolite on hydrolase (<bold>A and B</bold>) and cyclase (<bold>C</bold>) activities (n=3 experiments/technical replicates). (<bold>D and E</bold>) Effect of uracil and 1,3-dihydroimidazol-2-one (1,3-DHI-2-one) on hydrolase and cyclase activities of wild-type (WT) lung tissues (n=3 experiments/technical replicates). Data are mean ± s.e.m.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To identify the functional group for CD38 inhibition, we tested additional xanthine analogs (oxypurinol and caffeine) and the methyl analogs (caffeine metabolites) of sUA including 1-methyluric acid (1-MU), 1,3-dimethyluric acid (1,3-DMU), 1,7-dimethyluric acid (1,7-DMU), and 1,3,7-trimethyluric acid (1,3,7-TMU). The results showed that only sUA analogs inhibited CD38 activity (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). A structural comparison (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) indicated that 1,3-dihydroimidazol-2-one (1,3-DHI-2-one) is the main functional group, as all other purines and derivates lacking this group failed to inhibit CD38 activity. In addition, the ring-opening of the uracil group after sUA conversion to allantoin abrogated this inhibitory potential. Uracil or 1,3-DHI-2-one (<xref ref-type="fig" rid="fig2">Figure 2E</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D and E</xref>) alone did not affect CD38 activity. Therefore, the adjacent uracil-like heterocycles are also essential for CD38 inhibition.</p></sec><sec id="s2-3"><title>sUA at physiological levels limits NAD<sup>+</sup> degradation by directly inhibiting CD38</title><p>Next, we explored the effect of sUA on NAD<sup>+</sup> availability, as CD38 is a key enzyme in degrading NAD<sup>+</sup> and its precursor NMN (<xref ref-type="bibr" rid="bib12">Chini et al., 2020</xref>). sUA boosted intracellular NAD<sup>+</sup> in A549 and THP-1 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>) without affecting the activities of nicotinamide phosphoribosyltransferase (NAMPT) and poly(ADP-ribose) polymerase (PARP) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A and C</xref>), two key enzymes involved in NAD<sup>+</sup> synthesis and metabolism, which suggests CD38 as a main target of sUA in regulating NAD<sup>+</sup> availability. Given that the physiological concentrations of hypoxanthine and xanthine are generally within 20 μM, both NAMPT and PARP might not be affected by purine metabolism under physiological conditions (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2B and D</xref>). Thus, we further investigated whether CD38 mediates the effect of sUA on NAD<sup>+</sup> degradation. Short-term and moderate ‘sUA-supplementation’ model was constructed by gavage of inosine and oxonic acid (OA, a uricase inhibitor with a K<sub>i</sub> in the nanomolar range; <xref ref-type="bibr" rid="bib24">Fridovich, 1965</xref>) in mice with ‘natural hypouricemia’ (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5C</xref>). The plasma sUA levels (around 120 μM) in our models were close to the minimum physiological concentrations in humans but were markedly lower than that in other long-term and hyperuricemia-associated disease models in rodents, which enabled us to evaluate the physiologically inhibitory effect of sUA on CD38 activity. Although OA was a weak inhibitor of CD38 with an IC<sub>50</sub> in the millimolar range (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A and B</xref>), it seemed unlikely to affect CD38 activity in our models because of the incomplete inhibition of uricase, as evidenced by plasma sUA (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3C</xref>). Although short-term administration of OA alone failed to increase plasma sUA levels, we used it as the background for metabolic studies in mice to exclude potential interference.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Soluble uric acid (sUA) physiologically limits NAD<sup>+</sup> degradation via CD38 inhibition.</title><p>Wild-type (WT) and CD38 knockout (KO) mice (10- to 12-week-old) received oral administration of saline, oxonic acid (OA), or OA plus inosine (Ino) twice (1-day moderate sUA supplementation). (<bold>A–D</bold>) Effect of 1-day sUA supplementation on plasma sUA (<bold>A</bold>) and whole blood NAD<sup>+</sup> (<bold>B</bold>), nicotinamide mononucleotide (NMN) (<bold>C</bold>), and cyclic ADP-ribose (cADPR) (<bold>D</bold>) levels in WT and CD38 KO mice (WT-Saline: n=8 mice, WT-OA: n=9 mice, WT-OA+Ino: n=9 mice, KO-Saline: n=6 mice, KO-OA: n=8 mice, KO-OA+Ino: n=8 mice). (<bold>E</bold>) Effect of 1-day or 3-day release on whole blood NAD<sup>+</sup>, NMN, cADPR, and plasma sUA levels in WT mice that received 1-day supplementation (WT-Saline: n=6 mice, WT-OA: n=8 mice, WT-OA+Ino: n=8 mice). (<bold>F</bold>) Effect of sUA (100, 200, or 500 μM) and other ligands (analogs at 500 μM, 78c, a CD38 inhibitor, at 0.5 μM) on NAD<sup>+</sup> degradation by recombinant hCD38 (n=5 independent samples). Data are mean ± s.e.m. Significance was tested using two-way ANOVA (<bold>A–D</bold>), Kruskal-Wallis test, or one-way ANOVA with Tukey’s multiple comparisons test (<bold>E and F</bold>). NS, not significant. Statistical difference (<bold>A–D</bold>) between OA and OA+Ino groups in WT or KO mice (saline alone group excluded) was also analyzed by two-tailed unpaired t-test or Mann-Whitney test; WT mice: p&lt;0.0001 (<bold>A</bold>), p=0.0056 (<bold>B</bold>), or 0.0351 (<bold>C</bold>); KO mice: p=0.0003 (<bold>A</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Effect of soluble uric acid (sUA) on intracellular NAD<sup>+</sup> levels in A549 and THP-1 cells.</title><p>(<bold>A</bold>) Effect of sUA on intracellular NAD<sup>+</sup> levels of A549 cells (n=5 biologically independent samples). (<bold>B</bold>) Effect of sUA pre-incubation on intracellular NAD<sup>+</sup> levels of THP-1 cells. Naïve THP-1 cells were incubated with sUA (0–10 mg/dL) for 2 hr, then the cells were washed twice with sterile PBS and stimulated with monosodium urate (MSU) crystals (200 μg/mL), crude lipopolysaccharide (cLPS) (20 μg/mL), zymosan (50 μg/mL), or ATP (2 mM) for 6 hr (n=6 biologically independent samples). Data are mean ± s.e.m. Significance was tested using one-way ANOVA with Dunnett’s multiple comparisons test (<bold>A and B</bold>) or Kruskal-Wallis test (cLPS groups in <bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Effect of soluble uric acid (sUA) and its precursors and metabolite on nicotinamide phosphoribosyltransferase (NAMPT) and poly(ADP-ribose) polymerase (PARP) activities.</title><p>(<bold>A and B</bold>) NAMPT activity (n=4 technical replicates). (<bold>C and D</bold>) PARP activity. 3-Aminobenzamide is a PARP inhibitor (n=4 technical replicates). Data are mean ± s.d. (<bold>A and C</bold>) or mean ± s.e.m. (<bold>B and D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Effect of oxonic acid (OA) on CD38 activity and plasma soluble uric acid (sUA) levels.</title><p>(<bold>A and B</bold>) Hydrolase and cyclase activities of lung tissues from wild-type (WT) mice in the presence of OA (0–5 mM) (n=3 experiments/technical replicates). (<bold>C</bold>) Effect of OA administration on plasma sUA levels in WT mice (10- to 12-week-old) that received oral administration of inosine. In saline group, the mice received oral administration and intraperitoneal injection of saline. In OA p.o. group, the mice received oral administration of inosine (1.5 g/kg) and OA (1.5 g/kg) (the same treatment in our models), and intraperitoneal injection of saline. In OA i.p. group, the mice received oral administration of inosine (1.5 g/kg), and intraperitoneal injection of OA (0.25 g/kg). Four hours after treatment, plasma sUA was measured (n=5–8 mice per group). Data are mean ± s.d. (<bold>A and B</bold>) or mean ± s.e.m. (<bold>C</bold>). Significance was tested using Brown-Forsythe and Welch ANOVA tests (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Effect of soluble uric acid (sUA) at physiological levels on NAD<sup>+</sup> degradation under inflammatory conditions.</title><p>(<bold>A–D</bold>) Effect of 1-day sUA supplementation on plasma sUA (<bold>A</bold>) and whole blood NAD<sup>+</sup> (<bold>B</bold>), nicotinamide mononucleotide (NMN) (<bold>C</bold>), and cyclic ADP-ribose (cADPR) (<bold>D</bold>) levels in wild-type (WT) and CD38 knockout (KO) mice (10- to 12-week-old) under inflammatory conditions. The mice received 1-day sUA supplementation. Two hours after the last treatment, the mice were intraperitoneally stimulated with sterile PBS or crude lipopolysaccharide (cLPS) (2 mg/kg) for 6 hr (WT-oxonic acid [OA]: n=6 mice, WT-OA+cLPS: n=11 mice, WT-OA+Ino+cLPS: n=12 mice, KO-OA: n=6 mice, KO-OA+cLPS: n=8 mice, KO-OA+Ino+cLPS: n=8 mice). (<bold>E–H</bold>) Effect of 1-day treatment of OA or inosine (Ino) on plasma sUA (<bold>E</bold>) and whole blood NAD<sup>+</sup> (<bold>F</bold>), NMN (<bold>G</bold>), and cADPR (<bold>H</bold>) levels in WT mice (10- to 12-week-old) under inflammatory conditions. The mice received 1-day treatment of OA or Ino (from the evening of day 0 to the morning of day 1). Two hours after the last treatment, the mice were intraperitoneally stimulated with sterile PBS or cLPS (2 mg/kg) for 6 hr (n=6 mice in Saline+cLPS group, n=5 mice in other groups). Data are mean ± s.e.m. Significance was tested using two-way ANOVA with Tukey’s multiple comparisons test (<bold>A–D</bold>), or one-way ANOVA with Tukey’s multiple comparisons test (<bold>E–H</bold>). Statistical difference (<bold>A–D</bold>) between OA+cLPS and OA+Ino+cLPS groups in WT or KO mice (OA alone group excluded) was also analyzed by two-tailed unpaired t-test (with Welch’s correction when applicable) or Mann-Whitney test; WT mice: p&lt;0.0001 (<bold>A</bold>), or p=0.0092 (<bold>B</bold>), 0.0221 (<bold>D</bold>); KO mice: p=0.0004 (<bold>A</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp4-v1.tif"/></fig><fig id="fig3s5" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 5.</label><caption><title>Effect of 1-, 3-, and 7-day soluble uric acid (sUA) supplementation on NAD<sup>+</sup>, nicotinamide mononucleotide (NMN), and sUA levels in whole blood and tissues.</title><p>Wild-type (WT) and CD38 knockout (KO) mice (10- to 12-week-old) received oral administration of saline, oxonic acid (OA), or OA plus inosine (Ino) twice daily for 1, 3, or 7 days. Four hours after the last treatment, the mice were sacrificed. In 1-day model, the mice were treated from the evening of day 0 to the morning of day 1. (<bold>A</bold>) Effect of 1-day sUA supplementation on tissue NAD<sup>+</sup>, NMN, and sUA levels (n=5 male mice per group). (<bold>B</bold>) Effect of 3-day sUA supplementation on tissue NAD<sup>+</sup>, NMN, and sUA levels (n=5 male mice per group). (<bold>C–F</bold>) Effect of 3-day sUA supplementation on plasma sUA (<bold>C</bold>), whole blood NAD<sup>+</sup> (<bold>D</bold>), NMN (<bold>E</bold>), and cyclic ADP-ribose (cADPR) (<bold>F</bold>) levels (WT-Saline: n=6 mice, WT-OA: n=8 mice, WT-OA+Ino: n=8 mice, KO-Saline: n=6 mice, KO-OA: n=8 mice, KO-OA+Ino: n=8 mice). (<bold>G–I</bold>) Effect of 7-day sUA supplementation on tissue NAD<sup>+</sup> and sUA levels (n=5 male mice per group). Data are mean ± s.e.m. Significance was tested using two-way ANOVA with Tukey’s multiple comparisons test (<bold>A–H</bold>), Kruskal-Wallis test or one-way ANOVA with Dunnett’s multiple comparisons test (<bold>I</bold>). Statistical difference (<bold>C–H</bold>) between OA and OA+Ino groups in WT or KO mice (saline alone group excluded) was also analyzed by two-tailed unpaired t-test; WT mice: p&lt;0.0001 (<bold>C</bold>), or p=0.0058 (<bold>D</bold>), 0.0453 (<bold>E</bold>), 0.0083 (G, left panel), 0.0036 (H, left panel); KO mice: p=0.0004 (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp5-v1.tif"/></fig><fig id="fig3s6" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 6.</label><caption><title>No effect of 1- to 7-day soluble uric acid (sUA) supplementation on serum IL-1β production.</title><p>Wild-type (WT) and CD38 knockout (KO) mice (10- to 12-week-old) received oral administration of saline, oxonic acid (OA), or OA plus inosine (Ino) twice daily for 1, 3, or 7 days. Four hours after the last treatment, serum was collected for IL-1β measurement (n=5 male mice per group).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp6-v1.tif"/></fig><fig id="fig3s7" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 7.</label><caption><title>Soluble uric acid (sUA) limits nicotinamide mononucleotide (NMN) degradation via CD38 inhibition.</title><p>(<bold>A</bold>) Effect of sUA on recombinant hCD38-mediated NMN (200 μM) degradation in medium (n=8 independent samples). (<bold>B</bold>) Effect of sUA (100, 200, and 500 μM) or 78c (0.5 μM) on intracellular NAD<sup>+</sup> levels of wild-type (WT) bone marrow-derived macrophages (BMDMs) treated with NMN. WT BMDMs were primed with 100 ng/mL ultrapure lipopolysaccharide (LPS) for 8 hr (n=6 biologically independent samples). (<bold>C–E</bold>) Effect of sUA on extracellular NMN degradation in WT (<bold>C</bold>) or CD38 KO BMDMs in the absence (<bold>D</bold>) or presence (<bold>E</bold>) of recombinant hCD38 (10 ng/mL). BMDMs were primed with 100 ng/mL ultrapure LPS for 8 hr before metabolic assays (n=6 biologically independent samples in <bold>C</bold> and <bold>D</bold>), n=8 biologically independent samples in (<bold>E</bold>). Data are mean ± s.e.m. Significance was tested using one-way ANOVA with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig3-figsupp7-v1.tif"/></fig></fig-group><p>One- or 3-day moderate sUA supplementation slightly but significantly increased whole blood NAD<sup>+</sup> levels in wild-type (WT) mice but not in CD38 knockout (KO) mice (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>; <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5C and D</xref>). Similar results were also observed under inflammatory conditions (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A and B</xref>; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4D and E</xref>), and OA or inosine alone had no interference (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4E–H</xref>). This indicates that CD38 mediates, at least in part, the suppressive effect of sUA on NAD<sup>+</sup> degradation. The suppression of NAD<sup>+</sup> degradation by the sUA-CD38 interaction was validated by a decrease in cADPR production under inflammatory conditions (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4D</xref>) but not under non-inflammatory conditions (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5F</xref>), possibly because of physiological compensation via other cADPR synthases. However, sUA had a minor effect on NMN levels in vivo (<xref ref-type="fig" rid="fig3">Figure 3C</xref>; <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4C</xref>; <xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5E</xref>; <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4F</xref>), likely due to the rapid conversion of NMN to NAD<sup>+</sup> (<xref ref-type="bibr" rid="bib58">Mills et al., 2016</xref>). Notably, WT and CD38 KO mice showed similar NAD<sup>+</sup> baselines in whole blood, suggesting that the metabolic background has been reprogrammed in CD38 KO mice; for instance, sirtuins with higher activity in CD38 KO mice (<xref ref-type="bibr" rid="bib8">Camacho-Pereira et al., 2016</xref>) may consume more NAD<sup>+</sup>. Moreover, sUA release in vivo showed that both plasma sUA and whole blood NAD<sup>+</sup> gradually returned to their initial levels (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), which confirmed the reversible regulation of NAD<sup>+</sup> availability by sUA and excluded potential interference from the gene regulation involved in other bioconversion pathways of NAD<sup>+</sup>. Metabolic assays using recombinant hCD38 further verified that increased NAD<sup>+</sup> availability is mediated by direct CD38-sUA interaction (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>In contrast, the tissue levels of NAD<sup>+</sup> and NMN were not increased in 1- and 3-day sUA-supplementation models, probably because the tissue uptake of sUA was physiologically saturated before treatment (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5A and B</xref>). The NAD<sup>+</sup> levels in the brain and heart appeared to be elevated in 7-day model (<xref ref-type="fig" rid="fig3s5">Figure 3—figure supplement 5G–I</xref>). Thus, the sUA-CD38 interaction in the circulation may indirectly increase tissue NAD<sup>+</sup> availability. Our models within 7 days did not show an increase in serum IL-1β production (<xref ref-type="fig" rid="fig3s6">Figure 3—figure supplement 6</xref>), but we did not prolong the treatment time because long-term administration of OA might induce renal damage with concomitant inflammation related to cell death.</p><p>Considering the rapid conversion of NMN to NAD<sup>+</sup> in vivo, we assessed the effect of sUA on extracellular NMN degradation in vitro. sUA directly inhibited NMN degradation by recombinant hCD38 (<xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7A</xref>). Whereas sUA or another CD38 inhibitor failed to boost intracellular NAD<sup>+</sup> in primed WT bone marrow-derived macrophages (BMDMs) treated with NMN (<xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7B</xref>). This is likely because another NAD<sup>+</sup>-consuming enzyme, PARP1, is activated (<xref ref-type="bibr" rid="bib59">Minhas et al., 2019</xref>) and the NMN transporter expression is very low in BMDMs (<xref ref-type="bibr" rid="bib12">Chini et al., 2020</xref>). Importantly, sUA increased extracellular NMN availability in WT BMDMs but not in CD38 KO BMDMs (<xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7C and D</xref>). The addition of recombinant hCD38 restored the suppressive effect of sUA on extracellular NMN degradation in CD38 KO BMDMs (<xref ref-type="fig" rid="fig3s7">Figure 3—figure supplement 7E</xref>). Accordingly, sUA may also increase NAD<sup>+</sup> availability by inhibiting CD38-medaited NMN degradation.</p></sec><sec id="s2-4"><title>sUA physiologically prevents excessive inflammation by interacting with CD38</title><p>NAD<sup>+</sup> is crucial for the activity of sirtuins that limit the NLRP3 inflammasome activation (<xref ref-type="bibr" rid="bib30">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Misawa et al., 2013</xref>), and cADPR may regulate calcium signaling to promote cytokine production (<xref ref-type="bibr" rid="bib61">Murakami et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Zeidler et al., 2022</xref>). Therefore, CD38 plays a key role in inflammation via NAD<sup>+</sup> metabolism (<xref ref-type="bibr" rid="bib66">Piedra-Quintero et al., 2020</xref>). We confirmed the role of CD38 in the NLRP3 inflammasome activation. CD38 KO reduced IL-1β release driven by several inflammasome activators and the fungal component zymosan in primed BMDMs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). However, pre-incubation with sUA at physiological levels hardly suppressed inflammasome activation in primed WT BMDMs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). sUA uptake was very low in primed WT BMDMs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>), suggesting a crucial role of intracellular sUA in regulating inflammasome activation in vitro. However, extracellular sUA may inhibit CD38-mediated NMN degradation to increase NAD<sup>+</sup> levels in vivo, thus limiting excessive inflammation via sirtuins signaling. In fact, we noticed that sUA pre-incubation moderately limited IL-1β release in primed THP-1 cells (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>), and CD38 blockade abrogated this effect without reducing sUA uptake (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B and C</xref>), which suggests CD38 as a key mediator in the immunosuppressive effect of sUA at physiological levels. Notably, sUA did not induce IL-1β release in primed WT BMDMs and THP-1 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>; <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>). The pro-inflammatory potential of sUA, especially at supraphysiological levels, has been challenged by the improper preparation of aqueous solution (MSU crystal precipitation) in basic studies (<xref ref-type="bibr" rid="bib2">Alberts et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>). We also confirmed that long-term storage at 4°C promoted crystal precipitation in high-concentration sUA stock solutions (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>To reveal the role of sUA-CD38 interaction in regulating inflammation and innate immunity, at first, we stimulated WT and CD38 KO mice with crude lipopolysaccharide (cLPS) after 1-day sUA supplementation. OA was used as the background in mice to exclude its interference. Plasma sUA at the minimum physiological levels of humans (OA plus inosine group) suppressed cLPS-induced production of serum IL-1β and IL-18 in WT mice without affecting inflammasome-independent TNF-α levels, and the suppressive effects were abrogated in CD38 KO mice (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>), demonstrating that sUA physiologically limits cLPS-induced systemic inflammation via CD38. sUA immunosuppression may be partially mediated by increased NAD<sup>+</sup> levels and decreased cADPR production in whole blood after sUA-CD38 interaction (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4B and D</xref>). sUA hardly limited high-dose cLPS-induced systemic inflammation (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4A–C</xref>), although plasma sUA and whole blood NAD<sup>+</sup> levels were increased (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4D and E</xref>). In addition, high-dose cLPS, with or without sUA supplementation, did not affect cADPR levels (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4G</xref>), suggesting some CD38-independent inflammatory mechanisms.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Soluble uric acid (sUA) physiologically prevents excessive inflammation by interacting with CD38.</title><p>Wild-type (WT) and CD38 knockout (KO) mice (10- to 12-week-old) received 1-day moderate sUA supplementation, plasma sUA was increased to the minimum physiological levels of humans in oxonic acid (OA) plus inosine (Ino) groups. Then, the mice were stimulated with crude lipopolysaccharide (cLPS) (2 mg/kg) or monosodium urate (MSU) crystals (2 mg/mouse) for 6 hr. (<bold>A–C</bold>) Effect of sUA at physiological levels on serum levels of IL-1β (<bold>A</bold>), IL-18 (<bold>B</bold>), and TNF-α (<bold>C</bold>) in mice with cLPS-induced systemic inflammation (WT-OA: n=6 mice, WT-OA+cLPS: n=11 mice, WT-OA+Ino+cLPS: n=12 mice, KO-OA: n=6 mice, KO-OA+cLPS: n=8 mice, KO-OA+Ino+cLPS: n=8 mice). (<bold>D–H</bold>) Effect of sUA at physiological levels on IL-1β (<bold>D</bold>), IL-6 (<bold>E</bold>), and CXCL1 (<bold>F</bold>) levels and recruitment of viable cells (red blood cells excluded) (<bold>G</bold>) and neutrophils (<bold>H</bold>) in peritoneal lavage fluid from the mice with MSU crystal-induced peritonitis (WT-OA: n=6 mice, WT-OA+MSU: n=12 mice, WT-OA+Ino+MSU: n=13 mice, KO-OA: n=6 mice, KO-OA+MSU: n=10 mice, KO-OA+Ino+MSU: n=10 mice). Data are mean ± s.e.m. Significance was tested using two-way ANOVA with Tukey’s multiple comparisons test. NS, not significant. Statistical difference between OA+cLPS (or MSU) and OA+Ino+cLPS (or MSU) groups in WT or KO mice (OA alone group excluded) was also analyzed by two-tailed unpaired t-test (with Welch’s correction when applicable) or Mann-Whitney test; WT mice: p=0.0398 (<bold>A</bold>), 0.0383 (<bold>B</bold>), 0.0407 (<bold>D</bold>), 0.0417 (<bold>E</bold>), 0.0222 (<bold>G</bold>), or 0.0205 (<bold>H</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Effect of CD38 knockout (KO) or soluble uric acid (sUA) pre-incubation on IL-1β release in primed bone marrow-derived macrophages (BMDMs).</title><p>(<bold>A</bold>) Effect of CD38 KO on IL-1β release in primed BMDMs. Wild-type (WT) and KO BMDMs were primed with 100 ng/mL ultrapure lipopolysaccharide (LPS) for 4 hr, then primed BMDMs were challenged by ATP (5 mM, 30 min), nigericin (3 μM, 2 hr), monosodium urate (MSU) crystals (200 μg/mL, 6 hr), crude LPS (cLPS) (20 μg/mL, 6 hr), and zymosan (50 μg/mL, 4 hr). US means unstimulated (n=8 biologically independent samples in ATP and nigericin groups, n=6 biologically independent samples in other groups). (<bold>B–D</bold>) Effect of sUA pre-incubation on IL-1β release and intracellular sUA levels in primed BMDMs. WT BMDMs were primed with 100 ng/mL ultrapure LPS for 4 hr. (<bold>B</bold>) The cells were pre-incubated with or without sUA (100 or 200 μM) for 2 hr. Then, the cells were washed twice with sterile PBS and were stimulated with nigericin (3 μM, 2 hr), MSU crystals (200 μg/mL, 4 hr), or cLPS (1 μg/mL, 4 hr). (<bold>C and D</bold>) Primed BMDMs were directly incubated with sUA (100, 200, and 500 μM) or MSU crystals (100 μg/mL) for 6 hr in <bold>C</bold>, 2 or 15 hr in <bold>D</bold>. US means unstimulated (n=6 biologically independent samples in <bold>B</bold> and <bold>C</bold>, n=3 biologically independent samples in <bold>D</bold>). Data are mean ± s.e.m. Significance was tested using two-tailed unpaired t-test and Mann-Whitney test (ATP and zymosan) (<bold>A</bold>), or one-way ANOVA with Dunnett’s multiple comparisons test (<bold>B–D</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Effect of soluble uric acid (sUA) pre-incubation and CD38 blockade on IL-1β release in primed THP-1 cells.</title><p>THP-1 cells were primed with 0.5 μM phorbol 12-myristate 13-acetate (PMA) for 3 hr the day before stimulation. (<bold>A</bold>) Primed THP-1 cells were pre-incubated with sUA (0–10 mg/dL) for 2 hr, then the cells were washed twice with sterile PBS and challenged by monosodium urate (MSU) crystals (200 μg/mL), crude lipopolysaccharide (cLPS) (20 μg/mL), zymosan (50 μg/mL), and ATP (2 mM) for 4 hr (n=6 biologically independent samples). (<bold>B and C</bold>) Primed THP-1 cells were treated without or with 2 μM 78c (CD38 blockade by the highly specific and potent inhibitor of CD38) for 2 hr. Then, the cells were pre-incubated with blank medium or sUA for 2 hr. The cells were washed twice with sterile PBS. The washed cells were challenged by MSU crystals (200 μg/mL, 4 hr) for IL-1β measurement (<bold>B</bold>) or were directly used for sUA uptake measurement without MSU crystal stimulation (<bold>C</bold>). 78c was used in all steps for CD38 blockade groups, including sUA pre-incubation and MSU crystal stimulation (n=6 biologically independent samples). Data are mean ± s.e.m. Significance was tested using Kruskal-Wallis test (ATP groups in <bold>A</bold>), one-way ANOVA with Dunnett’s multiple comparisons test (<bold>A</bold>), or two-way ANOVA with Tukey’s multiple comparisons test (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Crystal precipitation in high-concentration soluble uric acid (sUA) stock solutions after long-term storage.</title><p>sUA stock solutions in NaOH were prepared without pH adjustment. Crystals were immediately precipitated after dissolution in 50 mg/mL tube. Visible crystals were observed in 5 mg/mL tube after 2-month storage at 4°C (before taking the picture, the tube was slightly shaken to resuspend the crystals on the bottom).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>One-day soluble uric acid (sUA) supplementation fails to prevent high-dose crude lipopolysaccharide (cLPS)-induced systemic inflammation.</title><p>Wild-type (WT) mice (10- to 12-week-old) received 1-day treatment of oxonic acid (OA) or OA plus inosine (Ino), 2 hr after the last treatment, the mice were intraperitoneally stimulated with sterile PBS or cLPS (20 mg/kg) for 4 hr (n=5 mice per group). (<bold>A–C</bold>) Serum IL-1β (<bold>A</bold>), IL-18 (<bold>B</bold>), and TNF-α (<bold>C</bold>) were measured. (<bold>D–G</bold>) Plasma sUA (<bold>D</bold>), whole blood NAD<sup>+</sup> (<bold>E</bold>), nicotinamide mononucleotide (NMN) (<bold>F</bold>), and cyclic ADP-ribose (cADPR) (<bold>G</bold>) levels were measured. Data are mean ± s.e.m. Significance was tested using one-way ANOVA with Tukey’s multiple comparisons test (<bold>A</bold> and <bold>C–G</bold>) or Kruskal-Wallis test (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp4-v1.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 5.</label><caption><title>Oxonic acid (OA) or inosine (Ino) alone does not limit crude lipopolysaccharide (cLPS)-induced systemic inflammation and monosodium urate (MSU) crystal-induced peritonitis.</title><p>Wild-type (WT) mice (10- to 12-week-old) received 1-day oral administration of saline, OA, or Ino, 2 hr after the last treatment, the mice were intraperitoneally stimulated with sterile PBS, cLPS (2 mg/kg), or monosodium urate (MSU) crystals (2 mg/mouse) for 6 hr. (<bold>A–C</bold>) Serum IL-1β (<bold>A</bold>), IL-18 (<bold>B</bold>), and TNF-α (<bold>C</bold>) levels in mice with cLPS-induced systemic inflammation were measured (n=6 mice in Saline+cLPS group, n=5 mice in other groups). (<bold>D–H</bold>) IL-1β (<bold>D</bold>), IL-6 (<bold>E</bold>), CXCL1 (<bold>F</bold>), and the number of viable cells (red blood cells excluded) (<bold>G</bold>) and neutrophils (<bold>H</bold>) in peritoneal lavage fluid from the mice with MSU crystal-induced peritonitis were measured (n=5 mice per group). Data are mean ± s.e.m. Significance was tested using one-way ANOVA with Tukey’s (<bold>A, C–H</bold>) multiple comparisons test, or Kruskal-Wallis test (<bold>B</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp5-v1.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 6.</label><caption><title>Potential mechanism of the paradox in gout therapy (urate-lowering therapy).</title><p>The soluble uric acid (sUA)-monosodium urate (MSU) crystal curve in this figure was also described in our previous review article. The curve was minorly adapted and was permitted to be published in this eLife paper.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-96962-fig4-figsupp6-v1.tif"/><permissions><copyright-statement>© 2024, Elsevier</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Elsevier</copyright-holder><license><license-p>Reprinted from Figure 4D in <xref ref-type="bibr" rid="bib77">Wen et al., 2024</xref> with permission from Elsevier; further reproduction of this figure would need permission from the copyright holder.</license-p></license></permissions></fig></fig-group><p>Recently, crystal-free hyperuricemia has been shown to rapidly inhibit neutrophil migration (<xref ref-type="bibr" rid="bib54">Ma et al., 2022</xref>), suggesting that some biological targets directly mediate sUA immunosuppression (<xref ref-type="bibr" rid="bib50">Lowell, 2022</xref>). CD38 is crucial for neutrophil recruitment (<xref ref-type="bibr" rid="bib64">Partida-Sánchez et al., 2001</xref>), we therefore investigated the effect of sUA on MSU crystal-induced peritonitis via CD38. After 1-day sUA supplementation, plasma sUA at the minimum physiological levels of humans (OA plus inosine group) inhibited the recruitment of viable cells and neutrophils and reduced the production of IL-1β and IL-6 in WT mice but not in CD38 KO mice (<xref ref-type="fig" rid="fig4">Figure 4D, E, G, and H</xref>), which verified the involvement of CD38 in the suppressive effect of sUA on inflammation and innate immunity. CXCL1 production (<xref ref-type="fig" rid="fig4">Figure 4F</xref>) was not affected by sUA, indicating that the sUA-CD38 interaction may inhibit circulating immune cells in response to chemokines. Moreover, sUA may interfere with the interaction between CD38 and adhesion molecules such as CD31 (<xref ref-type="bibr" rid="bib18">Deaglio et al., 2010</xref>; <xref ref-type="bibr" rid="bib17">Deaglio et al., 1998</xref>) to suppress immune cell migration. Intriguingly, intact IL-8 signaling has been reported in CD38 KO mice (<xref ref-type="bibr" rid="bib64">Partida-Sánchez et al., 2001</xref>), and sUA at a high concentration (595 μM) inhibits neutrophils in response to IL-8 (<xref ref-type="bibr" rid="bib54">Ma et al., 2022</xref>). Whereas we did not observe decreased neutrophil recruitment by sUA in CD38 KO mice, likely because plasma sUA levels (around 120 μM) in our models are insufficient to affect IL-8 signaling. In addition, we cannot exclude the possibility that sUA at supraphysiological levels interacts with other targets to regulate IL-8 signaling and β2-integrin, which requires further investigation in the future.</p><p>Inosine, an sUA precursor, may also exhibit anti-inflammatory effect by interacting with adenosine receptors (<xref ref-type="bibr" rid="bib27">Gomez and Sitkovsky, 2003</xref>). Scott et al. reported that after oral administration, serum inosine concentrations slightly increased and then rapidly returned to the initial levels in mice within 2 hr (<xref ref-type="bibr" rid="bib68">Scott et al., 2002</xref>). We stimulated the mice with cLPS or MSU crystals 2 hr after the second treatment, suggesting the negligible contribution of inosine. To verify this and exclude the potential contribution of OA, we evaluated the effects of 1-day treatment of inosine or OA on inflammation in vivo. The results showed that OA or inosine alone hardly affected cLPS-induced systemic inflammation (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5A–C</xref>) and MSU crystal-induced peritonitis (<xref ref-type="fig" rid="fig4s5">Figure 4—figure supplement 5D–H</xref>), as well as plasma sUA levels and whole blood NAD<sup>+</sup> metabolism under inflammatory conditions (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4E–H</xref>). Thus, these results suggested that sUA at physiological levels limits innate immunity to avoid excessive inflammation by interacting with CD38.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In the present study, we unveiled CD38 as a direct physiological target for sUA and thus defined its fundamental physiological functions in the regulation of NAD<sup>+</sup> availability and innate immunity, which promotes understanding of the molecular basis of sUA physiology as well as providing an important clue to explore the potential impact of abnormal sUA levels (independent of MSU crystals) on health and disease.</p><p>It has been reported that NAD<sup>+</sup> decline contributes to inflammation, aging-related dysfunction, and multiple diseases, including hearing loss, obesity, diabetes, kidney diseases, and cardiovascular diseases, in murine models (<xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>) and possibly even in humans (<xref ref-type="bibr" rid="bib67">Rajman et al., 2018</xref>). Accordingly, NAD<sup>+</sup> boosting by CD38 inhibitors has been a promising therapeutic strategy (<xref ref-type="bibr" rid="bib12">Chini et al., 2020</xref>; <xref ref-type="bibr" rid="bib11">Chini et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Escande et al., 2013</xref>; <xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>; <xref ref-type="bibr" rid="bib65">Peclat et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Tarragó et al., 2018</xref>). We discovered a structural feature for pharmacological inhibition of CD38 based on sUA analogs such as caffeine metabolites. Indeed, sUA and its analogs have similar functions, such as antioxidant property (<xref ref-type="bibr" rid="bib62">Nishida, 1991</xref>) and neuroprotective effects (<xref ref-type="bibr" rid="bib28">Haberman et al., 2007</xref>), supporting that they share a functional group, 1,3-DHI-2-one, that interacts with the same targets, including but not limited to CD38. Importantly, our results support that sUA at physiological levels limits CD38 activity to maintain NAD<sup>+</sup> availability, providing the molecular basis for sUA preventing NAD<sup>+</sup> decline-associated senescence and diseases. sUA levels seem to increase with age (<xref ref-type="bibr" rid="bib37">Iwama et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Kuzuya et al., 2002</xref>), raising a possibility that sUA elevation within physiological range is a compensatory response to aging in organisms. Given that CD38 expression is relatively low in young mice (<xref ref-type="bibr" rid="bib8">Camacho-Pereira et al., 2016</xref>), aged mice would be more appropriate to test this hypothesis. The apparent K<sub>i</sub> values imply that CD38 is completely inhibited by sUA in blood or in some tissues under physiological conditions; however, this might not be the case because other endogenous substance may also regulate CD38 activity (<xref ref-type="bibr" rid="bib10">Chini et al., 1997</xref>; <xref ref-type="bibr" rid="bib20">Dogan et al., 2002</xref>; <xref ref-type="bibr" rid="bib29">Hara-Yokoyama et al., 1996</xref>). In spite of this, altered sUA levels are able to indicate the changes in the activities of CD38 and other molecular targets of sUA, which partially explains the correlation between sUA homeostasis disruption and disease risk. For instance, abnormal reduction of sUA levels such as hypouricemia may result in higher CD38 activity in the circulation due to the reversible inhibitory effect of sUA, thus negatively influencing health as well as increasing the risk of certain diseases. However, it does not mean that higher sUA levels are better, because excessive elevation of sUA levels promotes the precipitation of MSU crystals. In addition, we cannot exclude the possibility that long-term and crystal-free hyperuricemia (&gt;420 μM) in humans may overly modulate additional unknown targets, especially in CD38-negative cells, thereby partially covering the CD38-mediated physiological functions of sUA. To identify more molecular targets for sUA, drug affinity responsive target stability (<xref ref-type="bibr" rid="bib49">Lomenick et al., 2009</xref>) and cellular thermal shift assay (<xref ref-type="bibr" rid="bib55">Martinez Molina et al., 2013</xref>), which detect the direct interactions between binding proteins and their ligands, may serve as alternative strategies.</p><p>Another unexpected observation is the restrictive effect of sUA at physiological levels on excessive inflammation, which is complementary to several recent studies regarding the immunosuppressive effect of crystal-free hyperuricemia in the host (<xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Ma et al., 2022</xref>). Similar to itaconate, an inhibitor of the NLRP3 inflammasome (<xref ref-type="bibr" rid="bib33">Hooftman et al., 2020</xref>), sUA production increases in activated macrophages (<xref ref-type="bibr" rid="bib36">Ives et al., 2015</xref>). It has been reported that intracellular sUA reduction promotes certain inflammatory responses (<xref ref-type="bibr" rid="bib36">Ives et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Kono et al., 2010</xref>), hence sUA at physiological levels may function as an endogenous regulator of inflammasomes to avoid excessive inflammation by inhibiting CD38 activity. On the other hand, chemical phase transition (crystal precipitation) is essential for sUA as a danger signal to trigger immune responses (<xref ref-type="bibr" rid="bib2">Alberts et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Ives et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Ma et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Shi, 2010</xref>; <xref ref-type="bibr" rid="bib69">Shi et al., 2003</xref>). We and another laboratory demonstrated that MSU crystals upregulate CD38 to promote inflammatory responses in primed macrophages (<xref ref-type="bibr" rid="bib76">Wen et al., 2021</xref>; <xref ref-type="bibr" rid="bib79">Yan, 2021</xref>). A recent study confirmed CD38 upregulation in gout patients and further validated the role of CD38 in experimental models of gouty inflammation induced by MSU crystals (<xref ref-type="bibr" rid="bib1">Alabarse et al., 2024</xref>). Importantly, in this study, we showed that CD38 mediates the opposite effects of sUA (especially at physiological levels) and MSU crystals on inflammation and innate immunity. Therefore, a sudden and rapid reduction of the circulating sUA levels by high-dose urate-lowering medications may disrupt the immune balance by rapidly releasing CD38 activity before MSU crystal dissolution (<xref ref-type="fig" rid="fig4s6">Figure 4—figure supplement 6</xref>), resulting in the increased risk of gout attack in the initiation of therapy (<xref ref-type="bibr" rid="bib5">Becker et al., 2005</xref>; <xref ref-type="bibr" rid="bib77">Wen et al., 2024</xref>), a well-known paradox in gout therapy. Several clinical studies even observed that blood sUA levels decrease during gout flares, and the resolution of gouty inflammation is coming with a recovery of sUA levels (<xref ref-type="bibr" rid="bib48">Logan et al., 1997</xref>; <xref ref-type="bibr" rid="bib73">Urano et al., 2002</xref>). Given the distinct effects of sUA and MSU crystals on certain targets, intracellular and/or extracellular microcrystals should be excluded when evaluating the pathological role of sUA at high levels in relevant studies. In addition, our findings also provide biological evidence for the neuroprotection of sUA. It has been reported that CD38 is involved in neurodegenerative diseases (<xref ref-type="bibr" rid="bib6">Blacher et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Meyer et al., 2022</xref>); thus, sUA in central nervous system tissues may directly inhibit CD38 activity to limit neuroinflammation and the progression of such diseases.</p><p>Previously, a physiological medium containing sUA was shown to inhibit UMP synthase to reshape cellular metabolism in vitro (<xref ref-type="bibr" rid="bib9">Cantor et al., 2017</xref>). We identified a unique sUA-CD38 interaction in this study, highlighting the physiologically essential role of sUA as a purine metabolite in sustaining life. Accumulated data suggests a remarkable overlap between the effects of sUA (<xref ref-type="bibr" rid="bib3">Álvarez-Lario and Macarrón-Vicente, 2010</xref>; <xref ref-type="bibr" rid="bib4">Ames et al., 1981</xref>; <xref ref-type="bibr" rid="bib14">Cutler et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Kutzing and Firestein, 2008</xref>; <xref ref-type="bibr" rid="bib43">Lai et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Linnerz et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Lu et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Ma et al., 2022</xref>; <xref ref-type="bibr" rid="bib68">Scott et al., 2002</xref>; <xref ref-type="bibr" rid="bib74">Wan et al., 2020</xref>) and CD38 inhibition/KO (<xref ref-type="bibr" rid="bib6">Blacher et al., 2015</xref>; <xref ref-type="bibr" rid="bib11">Chini et al., 2018</xref>; <xref ref-type="bibr" rid="bib32">Hogan et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Meyer et al., 2022</xref>) in counteracting excessive inflammation, aging, and certain diseases, which also strongly supports our current findings. It should be noticed that we used an exogenous compound as the background in mice to mimic the deficiency of uricase in humans, and tissue sUA levels were unchanged after sUA supplementation, suggesting some of the limitations in our models when evaluating the physiological relevance. Therefore, it is important to extend these studies to global sUA-depletion models in primates or uricase-transgenic mice. Moreover, the commercial recombinant hCD38 without a transmembrane region was partially used in this study, we cannot exclude the potential interaction between sUA and the transmembrane region of CD38, although comparable K<sub>i</sub> values were obtained in crude enzymes containing full-length CD38. In addition to identification of the allosteric sites of CD38, the crystallographic structure of the active full-length CD38-sUA complex should be captured using cryo-electron microscopy to elucidate the inhibitory mechanisms in the future. However, the present study clearly demonstrated that sUA at physiological levels directly inhibits CD38 and consequently limits NAD<sup>+</sup> degradation and excessive inflammation, suggesting that sUA is crucial for the physiological defense in humans against aging and diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Uric acid</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#U0881</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>)</td><td align="left" valign="bottom">Nacalai</td><td align="left" valign="bottom">Cat#24338-86</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-Nicotinamide mononucleotide (NMN)</td><td align="left" valign="bottom">BLD Pharmatech</td><td align="left" valign="bottom">Cat#BD116593</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cADP-Ribose (cADPR)</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat#sc-201512</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FYU-981</td><td align="left" valign="bottom">Fuji Yakuhin Co., Ltd.</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="." valign="bottom">78c</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#5.38763</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><italic>N</italic>-Cyclohexyl benzamide</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#R531332</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Inosine</td><td align="left" valign="bottom">Nacalai</td><td align="left" valign="bottom">Cat#07139-42</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hypoxanthine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#H-9636</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Xanthine</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#X0626</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Allantoin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#A-7878</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Adenosine</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">Cat#010-10491</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Guanosine</td><td align="left" valign="bottom">Wako</td><td align="left" valign="bottom">Cat#079-01111</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Uracil</td><td align="left" valign="bottom">FUJIFILM Wako</td><td align="left" valign="bottom">Cat#212-00062</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,3-Dihydroimidazol-2-one</td><td align="left" valign="bottom">BLD Pharmatech</td><td align="left" valign="bottom">Cat#BD00733674</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Oxypurinol</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#O-6881</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Caffeine</td><td align="left" valign="bottom">FUJIFILM Wako</td><td align="left" valign="bottom">Cat#031-06792</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1-Methyluric acid</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#M6885</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,3-Dimethyluric acid</td><td align="left" valign="bottom">Santa Cruz</td><td align="left" valign="bottom">Cat#sc-206240</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,7-Dimethyluric acid</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat#19584</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">1,3,7-Trimethyluric acid</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat#16949</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="char" char="hyphen" valign="bottom">8-Oxoguanine</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat#89290</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Oxonic acid potassium salt</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#156124</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">LPS from <italic>Escherichia coli</italic> 0111:B4 (crude LPS)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#L4130</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Ultrapure LPS from <italic>Escherichia coli</italic> 0111:B4</td><td align="left" valign="bottom">InvivoGen</td><td align="left" valign="bottom">Cat#tlrl-3pelps</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phorbol 12-Myristate 13-Acetate</td><td align="left" valign="bottom">FUJIFILM Wako</td><td align="left" valign="bottom">Cat#162-23591</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nigericin</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#N-7143</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">ATP</td><td align="left" valign="bottom">Oriental Yeast</td><td align="left" valign="bottom">Cat#45142000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Zymosan A from <italic>Saccharomyces cerevisiae</italic></td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#Z4250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nicotinamide 1, <italic>N</italic><sup>6</sup>-ethenoadenine dinucleotide (ε-NAD<sup>+</sup>)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#N2630</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Nicotinamide guanine dinucleotide (NGD)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat#N5131</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human CD38 protein</td><td align="left" valign="bottom">Sino Biological</td><td align="left" valign="bottom">Cat#10818-H08H</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Recombinant human M-CSF protein</td><td align="left" valign="bottom">Proteintech Group</td><td align="left" valign="bottom">Cat#HZ-1192</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Human IL-1β ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#DY201</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IL-1β ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#SMLB00C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IL-6 ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#DY406-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IL-18 ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#DY7625-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse TNF-α ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#DY410-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse CXCL1 ELISA Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#DY453-05</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Wright-Giemsa Stain Kit</td><td align="left" valign="bottom">ScyTek Laboratories</td><td align="left" valign="bottom">Cat#WGK-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CycLex NAMPT Colorimetric Assay Kit Ver.2</td><td align="left" valign="bottom">MBL</td><td align="left" valign="bottom">Cat#CY-1251V2</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">HT Universal Colorimetric PARP Assay Kit</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">Cat#4677-096-K</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">A549</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-185</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (human)</td><td align="left" valign="bottom">THP-1</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">TIB-202</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line<break/>(mouse)</td><td align="left" valign="bottom">ICR bone marrow-derived macrophages</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom">See more details in Preparation of BMDMs section</td></tr><tr><td align="left" valign="bottom">Strain, strain background (mouse)</td><td align="left" valign="bottom">ICR mice</td><td align="left" valign="bottom">Japan SLC, Inc</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (mouse)</td><td align="left" valign="bottom">CD38 KO ICR mice</td><td align="left" valign="bottom">Dr. Haruhiro Higashida, Kanazawa University</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism 9</td><td align="left" valign="bottom">GraphPad Software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com">https://www.graphpad.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Labsolutions software</td><td align="left" valign="bottom">Shimadzu</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.shimadzu.com">https://www.shimadzu.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">RF-6000 Spectrofluorophotometer</td><td align="left" valign="bottom">Shimadzu</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.shimadzu.com">https://www.shimadzu.com</ext-link></td><td align="left" valign="bottom">For the measurement of CD38 activity</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">LC-30A system</td><td align="left" valign="bottom">Shimadzu</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.shimadzu.com">https://www.shimadzu.com</ext-link></td><td align="left" valign="bottom">For LC-MS/MS analysis</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">LCMS-8050</td><td align="left" valign="bottom">Shimadzu</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.shimadzu.com">https://www.shimadzu.com</ext-link></td><td align="left" valign="bottom">For LC-MS/MS analysis</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>Male and female ICR (Institute of Cancer Research of the Charles River Laboratories, Inc, Wilmington, MA, USA) mice were initially purchased from Japan SLC, Inc. CD38 KO mice (ICR strain) were generated using the CRISPR/Cas9 method as previously described (<xref ref-type="bibr" rid="bib35">Ichinose et al., 2019</xref>). WT and CD38 KO mice were kept and bred at the Experimental Animal Center of Kanazawa University (Takara-machi campus). For animal experiments, all the mice (sex and age as indicated in respective figure legends) were transferred a week in advance and housed in the animal room of Research Center of Child Mental Development under standard conditions (24°C; 12 hr light/dark cycle, lights on at 8:30 am) with standard chow and water provided ad libitum. Male and female mice were separated after weaning and were equally used for experiments except when specified. In each experimental group, the mice were from different biological mothers. All animal experiments were approved by the Institutional Animal Care and Use Committee at Kanazawa University (AP-214243), and were performed in accordance with ARRIVE and the local guidelines.</p></sec><sec id="s4-2"><title>Cell culture</title><p>THP-1 and A549 cells were cultured in RPMI-1640 containing 10% FBS and 1% penicillin/streptomycin. Bone marrow cells and BMDMs were maintained in RPMI-1640 containing 10% FBS, 1% penicillin/streptomycin, and 50 μM 2-mercaptoethanol; macrophage colony stimulating factor (M-CSF) was used in the preparation of BMDMs.</p></sec><sec id="s4-3"><title>Measurement of CD38 activity</title><p>The hydrolase activity of CD38 was measured according to a previous report (<xref ref-type="bibr" rid="bib16">de Oliveira et al., 2018</xref>) with minor modifications. CD38 hydrolase activity was measured using 50 μM ε-NAD<sup>+</sup> as a substrate in hydrolase reaction buffer (250 mM sucrose, 40 mM Tris-HCl, pH 7.4). Briefly, cells or tissues were directly homogenized in blank reaction buffer on ice, and recombinant hCD38 was diluted in blank reaction buffer for subsequent assays. The tissue homogenates were centrifuged to collect the supernatant for enzyme assays. The loading volume of enzyme was 4–30 μL, the total volume of the reaction system was 3 mL. To detect enzyme inhibition, except when specified, the ligands were directly dissolved in hydrolase reaction buffer before pH adjustment, after which, the pH was immediately adjusted to 7.4. All reaction buffers, with or without ligands, were freshly prepared before each assay. For measurement of hydrolase activity, 3 mL reaction buffer containing enzyme, ε-NAD<sup>+</sup>, and ligands at indicated concentrations was maintained at 37°C with constant stirring.</p><p>The cyclase activity of CD38 was measured as previously described (<xref ref-type="bibr" rid="bib31">Higashida et al., 1999</xref>; <xref ref-type="bibr" rid="bib38">Jin et al., 2007</xref>). CD38 cyclase activity was measured using 60 μM NGD as a substrate in cyclase reaction buffer (100 mM KCl, 10 μM CaCl<sub>2</sub>, and 50 mM Tris-HCl, pH 6.6). Tissues were cut into pieces and suspended in the buffer (5 mM MgCl<sub>2</sub>, 10 mM Tris-HCl, pH 7.3) at 4°C for 30 min. Then, the suspension was homogenized on ice, and the supernatant was collected after centrifugation. To collect the crude membrane fractions, the supernatant was centrifuged at 105,000×<italic>g</italic> for 30 min. The final pellet was resuspended in 10 mM Tris-HCl solution (pH 6.6) for cyclase assay. Homogenates of THP-1 or A549 cells, and recombinant hCD38 were used directly for cyclase assays. The loading volume of enzyme was 4–20 μL, the total volume of reaction system was 3 mL. To detect enzyme inhibition, except when specified, the ligands were directly dissolved in cyclase reaction buffer before pH adjustment, after which, the pH was immediately adjusted to 6.6. All reaction buffers, with or without ligands, were freshly prepared before each assay. For measurement of cyclase activity, 3 mL reaction buffer containing enzyme, NGD, and ligands at indicated concentrations was maintained at 37°C with constant stirring.</p><p>The reaction buffer for hydrolase or cyclase assays was excited at 300 nm, and fluorescence emission was measured every second at 410 nm by Shimazu RF-6000 spectrofluorometer. Hydrolase or cyclase activity was calculated from the linear portion of the time course by fitting a linear function to the data points recorded within 5 min.</p><p>In this study, 8-OG and guanosine were tested only at 50 μM due to the limited solubility. Guanosine was dissolved in DMSO and diluted in the reaction buffer for subsequent assays. Other ligands such as sUA, inosine, hypoxanthine, xanthine, allantoin, adenosine, uracil, 1,3-DHI-2-one, oxypurinol, caffeine, 1-MU, 1,3-DMU, 1,7-DMU, and 1,3,7-TMU were tested at the concentrations as indicated.</p><p>For reversibility test, recombinant hCD38 was pre-incubated for 30 min in four conditions: (1) control reaction buffer; (2) in the presence of 100 μM substrate (ε-NAD<sup>+</sup> or NGD); (3) 500 μM sUA; (4) both substrate and sUA. Subsequently, the enzyme was diluted 100-fold in reaction buffer in the presence or absence of 500 μM sUA for activity assays using ε-NAD<sup>+</sup> or NGD. Naïve THP-1 and A549 cells were incubated with RPMI-1640 medium in the presence or absence of 500 μM sUA for 2 hr. The cells were collected and homogenized in the reaction buffer on ice with or without 500 μM sUA, samples were then diluted 100-fold in reaction buffer with or without 500 μM sUA for enzyme assay. Control group was not treated with sUA in all steps; sUA group was treated with sUA in each step; sUA release group was treated with sUA prior to dilution in sUA-free buffer for enzyme assays.</p></sec><sec id="s4-4"><title>Measurement of NAMPT and PARP activity</title><p>The activities of NAMPT and PARP were measured using commercial kits, HT Universal Colorimetric PARP Assay Kit, and CycLex NAMPT Colorimetric Assay Kit Ver.2. The solutions of ligands were freshly prepared (pH was adjusted to 7.4) and were immediately used for enzyme assays.</p></sec><sec id="s4-5"><title>Moderate sUA supplementation in mice</title><p>Plasma sUA levels in mice were increased to the minimum physiological levels of humans by moderate sUA supplementation. For 1-day sUA supplementation, WT and CD38 KO mice received oral administration of saline, OA (1.5 g/kg), or OA (1.5 g/kg) plus inosine (1.5 g/kg), the gavage volume was 5 mL/kg. Drug suspension in saline was freshly prepared and warmed to 37°C before each treatment. The mice received the first treatment on the evening (19:00) of the first day and the second treatment on the morning (9:00) of the second day. For 3- or 7-day sUA supplementation, WT and CD38 KO mice received the same treatment twice daily from the evening of the first day to the morning of the last day. Four hours after the last treatment, the mice were sacrificed and whole blood, serum, plasma, and tissues were collected for metabolic studies. For immunological studies, mice were stimulated with different ligands 2 hr after the second treatment on the morning (9:00) of the second day.</p></sec><sec id="s4-6"><title>sUA release in mice</title><p>WT mice received oral administration of saline, OA, or OA plus inosine (1-day supplementation model, as described above). One day (28 hr) or 3 days (76 hr) after the second treatment, the mice were sacrificed and whole blood and plasma were collected.</p></sec><sec id="s4-7"><title>cLPS-induced systemic inflammation</title><p>Plasma sUA levels in WT and CD38 KO mice were increased to the minimum physiological levels of humans by 1-day sUA supplementation (OA plus inosine). Two hours after the last treatment of OA, or OA plus inosine, the mice were intraperitoneally injected with sterile PBS or cLPS (2 or 20 mg/kg), the injection volume was 3 mL/kg. Four hours (20 mg/kg) or 6 hr (2 mg/kg) after stimulation, the mice were sacrificed and whole blood, plasma, and serum were collected.</p></sec><sec id="s4-8"><title>MSU crystal-induced peritonitis</title><p>Plasma sUA levels in WT and CD38 KO mice were increased to the minimum physiological levels of humans by 1-day sUA supplementation (OA plus inosine). Two hours after the last treatment of OA, or OA plus inosine, the mice were intraperitoneally injected with sterile PBS or MSU crystals (2 mg/mouse), and the injection volume was 200 μL/mouse. Six hours after stimulation, the mice were sacrificed and blood samples were collected. For each mouse, the peritoneal cavity was washed with 5 mL ice-cold sterile PBS, the supernatant was collected by centrifugation for subsequent ELISA, and cell pellets were used for total viable cell count by Trypan Blue staining. In brief, cell pellet from 1.5 mL of peritoneal lavage fluid was resuspended in RBC lysis buffer for 30 s, sterile PBS (ninefold volume) was added to terminate lysis. Afterward, the cells were centrifuged at 1000 rpm for 5 min and resuspended in sterile PBS for viable cell count. For neutrophil count, peritoneal lavage fluid was directly used for smears after appropriate dilution, and subsequently, Wright-Giemsa staining was performed according to the protocol provided by the manufacturer. Viable cells and neutrophils were counted by two investigators (one investigator did not participate in this project and was blind to the information of experimental groups), and the mean numbers were shown in the figures.</p></sec><sec id="s4-9"><title>ELISA</title><p>Human IL-1β, mouse IL-1β, IL-6, IL-18, TNF-α, and CXCL1 levels were measured according to the protocols provided by the manufacturer. Serum samples were diluted before ELISA when applicable. In this study, all the samples were frozen after collection and thawed before ELISA.</p></sec><sec id="s4-10"><title>Preparation of MSU crystals and sUA solution</title><p>MSU crystals were prepared by the recrystallization of oversaturated sUA according to a previous report (<xref ref-type="bibr" rid="bib56">Martinon et al., 2006</xref>). Improper preparation of sUA solution may introduce crystals to cause false-positive or false-negative results. It has been demonstrated that crystals may precipitate in sUA solution prepared by pre-warming to activate immune cells (<xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>). In this study, the sUA solution was prepared according to an improved protocol (<xref ref-type="bibr" rid="bib53">Ma et al., 2020</xref>). Briefly, we directly dissolved sUA at 0.5 mg/mL in blank RPMI-1640 medium by addition of NaOH, and adjusted the pH by HCl. Then, sUA solution was immediately filtered by 0.2 μm filters and diluted to experimental concentration (up to 10 mg/dL, 595 μM) for cell experiments. For all experiments, sUA solution was freshly prepared and used immediately.</p></sec><sec id="s4-11"><title>Preparation of BMDMs</title><p>Bone marrow cells were isolated from 10- to 12-week-old WT or CD38 KO mice (both male and female) by washing the marrow cavity with sterile PBS. The collected bone marrow cells were filtered by 70 μm strainers and then centrifuged at 1000 rpm, 4°C for 5 min. The cell pellet was resuspended in 2 mL red blood cell (RBC) lysis buffer for 30 s, then 8 mL complete RPMI-1640 medium (10% FBS, 1% penicillin/streptomycin, and 50 μM 2-mercaptoethanol) was added to terminate the lysis. After 5 min centrifugation at 1000 rpm, 4°C, the cells were resuspended in fresh complete RPMI-1640 medium and maintained for 4 hr in an incubator. Adherent cells were discarded, whereas non-adherent cells were cultured in complete RPMI-1640 medium containing 20 ng/mL M-CSF. After 3-day differentiation, the medium was replaced with fresh complete RPMI-1640 medium containing 20 ng/mL M-CSF. On the 7th day, BMDMs were collected for subsequent experiments. BMDMs were primed with 100 ng/mL ultrapure LPS for 4 hr for canonical inflammasome assay. For metabolic assay of NMN, BMDMs were primed with 100 ng/mL ultrapure LPS for 8 hr to induce higher protein expression of CD38.</p></sec><sec id="s4-12"><title>Intracellular NAD<sup>+</sup> assay</title><p>A549 cells were seeded in 24-well plates for NAD<sup>+</sup> assay. Briefly, when the confluence reached 80%, the culture medium in each well was discarded, and the cells were washed twice with sterile PBS and incubated in RPMI-1640 medium containing 1% FBS in the presence or absence of sUA (from 100 to 500 μM) for 20 hr. Then, the cells were washed twice with sterile PBS, after the second washing, PBS was completely removed and 100 μL 5% ice-cold perchloric acid (PCA) was added into each well. The plate was kept on ice for 2 hr, then cell samples were collected and centrifuged at 15,000 rpm, 4°C for 10 min. The supernatant was used for subsequent handling and measurement (see LC-MS/MS analysis).</p><p>Naïve THP-1 cells were pre-incubated with sUA (0–10 mg/dL) in RPMI-1640 medium containing 1% FBS for 2 hr, then the cells were washed twice with sterile PBS and stimulated with MSU crystals, cLPS, zymosan, or ATP for 6 hr. Subsequently, the cells were washed twice with sterile PBS, and then a total of 100 μL 5% ice-cold PCA was used to extract NAD<sup>+</sup> from cells in each well and medium as mentioned above.</p><p>WT BMDMs were primed with 100 ng/mL ultrapure LPS for 8 hr. Then, the cells were washed twice with sterile PBS. Afterward, the cells were incubated in control or 100 μM NMN-supplemented RPMI-1640 medium in the presence of sUA or 78c. After 6 hr incubation, the cells were washed twice with sterile PBS. Finally, cell samples for NAD<sup>+</sup> measurement were collected by 5% ice-cold PCA as mentioned above.</p></sec><sec id="s4-13"><title>Canonical inflammasome assay</title><p>Naïve THP-1 cells were primed with 0.5 μM phorbol 12-myristate 13-acetate for 3 hr the day before stimulation. Primed THP-1 cells were pre-incubated in RPMI-1640 medium in the presence or absence of sUA (5 or 10 mg/dL) for 2 hr. The cells were then washed twice with sterile PBS, and were stimulated with MSU crystals, cLPS, zymosan, and ATP in serum-free RPMI-1640 medium for 4 hr.</p><p>WT and CD38 KO BMDMs were primed with 100 ng/mL ultrapure LPS for 4 hr. Subsequently, primed BMDMs were pre-incubated with or without sUA for 2 hr, the cells were then washed twice with sterile PBS and were stimulated with nigericin, MSU crystals, or cLPS in serum-free RPMI-1640 medium.</p><p>After stimulation, the culture medium was collected and centrifuged at 3000 rpm, 4°C for 5 min, the supernatant was collected and stored at –30°C until ELISA.</p></sec><sec id="s4-14"><title>sUA uptake assay</title><p>WT BMDMs were primed with 100 ng/mL ultrapure LPS for 4 hr. Then, the cells were washed twice with sterile PBS, and maintained in RPMI-1640 medium containing sUA (100, 200, or 500 μM) for 2 or 15 hr. Subsequently, the cells were washed twice with ice-cold sterile PBS to terminate uptake, 100 μL 5% ice-cold PCA was added into each well. The plates were placed on ice for 2 hr, then cell samples were collected and centrifuged at 15,000 rpm, 4°C for 10 min. The supernatant was used for subsequent handling and measurement (see LC-MS/MS analysis).</p></sec><sec id="s4-15"><title>Metabolic assay of NAD<sup>+</sup></title><p>NAD<sup>+</sup> degradation by recombinant hCD38 was detected in hydrolase reaction buffer. At first, sUA (100, 200, and 500 μM) or other ligands at 500 μM in hydrolase reaction buffer (250 mM sucrose, 40 mM Tris) was freshly prepared, then the pH was immediately adjusted to 7.4 by HCl. Recombinant hCD38 was added into the buffer of experimental groups at 20 ng/mL, then the buffer was maintained at 37°C. The substrate NAD<sup>+</sup> was dissolved in hydrolase reaction buffer (pH 7.4) at 10 mM, and the pH was further adjusted to 7.4. The reaction was started with the addition of NAD<sup>+</sup> in the buffer for each group (final concentration is 200 μM), including control group (recombinant hCD38 free). All the buffers were incubated at 37°C with constant stirring. After 30 or 60 min, 20 μL reaction buffer was transferred into 180 μL of 5% ice-cold PCA, then vortexed for 30 s before 10 min centrifugation at 15,000 rpm, 4°C. The supernatant was further handled for NAD<sup>+</sup> measurement within 12 hr without freezing and thawing (see LC-MS/MS analysis).</p></sec><sec id="s4-16"><title>Metabolic assay of NMN</title><p>To prepare the reaction buffer, sUA was directly dissolved in blank RPMI-1640 medium by addition of NaOH, and the pH was immediately adjusted by HCl. After pH adjustment, the medium containing sUA was filtered by 0.2 μm filter and diluted as indicated. The medium containing 20 ng/mL recombinant hCD38 was then placed in a cell incubator. The reaction was started with the addition of NMN (final concentration was 200 μM). After incubation for 6 hr, 20 μL medium was transferred into 180 μL 5% ice-cold PCA, then vortexed for 30 s and centrifuged at 15,000 rpm, 4°C for 10 min. The supernatant was stored at –80°C until further handling for NMN measurement (see LC-MS/MS analysis).</p></sec><sec id="s4-17"><title>Extracellular NMN degradation</title><p>WT and CD38 KO BMDMs were primed with 100 ng/mL ultrapure LPS for 8 hr, then the cells were washed twice with sterile PBS. Primed BMDMs were maintained in RPMI-1640 medium supplemented with 100 μM NMN in the presence or absence of sUA. To restore the inhibitory effects of sUA on NMN degradation in KO BMDMs, recombinant hCD38 was added to the medium (final concentration was 10 ng/mL). After 6 hr incubation, culture medium was collected and centrifuged at 3000 rpm, 4°C for 5 min. Then, 20 μL of supernatant was transferred into 180 μL 5% ice-cold PCA, and was vortexed for 30 s and centrifuged at 15,000 rpm, 4°C for 10 min. The supernatant was stored at –80°C until further handling for NMN measurement.</p></sec><sec id="s4-18"><title>Handling of animal samples</title><p>The collected whole blood samples were immediately diluted 10-fold in 5% ice-cold PCA and homogenized on ice. After 10 min centrifugation at 15,000 rpm, 4°C, the supernatant was subpackaged for measurement or –80°C storage. For NAD<sup>+</sup> measurement in whole blood, the supernatant was handled without freezing and thawing and was measured within 24 hr of sample collection. For measurement of plasma sUA, after sample collection, we immediately diluted the plasma with 5% ice-cold PCA, after vortex, samples were centrifuged at 15,000 rpm, 4°C for 10 min, the collected supernatant was used for the subsequent handling and measurement within 24 hr.</p><p>After the collection of blood samples, the mice were immediately perfused with ice-cold sterile PBS. The tissue samples were collected, dried with tissue paper, and weighed. All the tissue samples were immediately homogenized in 5% ice-cold PCA on ice, then centrifuged at 15,000 rpm, 4°C for 10 min. The supernatant was collected and stored at –80°C until further handling for measurement (see LC-MS/MS analysis).</p></sec><sec id="s4-19"><title>LC-MS/MS analysis</title><p>As mentioned above, samples (cells, tissues, blood, or reaction buffer) were treated with ice-cold PCA, after extraction and centrifugation, the collected supernatant was appropriately diluted in 5% ice-cold PCA when applicable, and then was vortexed for 30 s and centrifuged at 15,000 rpm, 4°C for 5 min. Afterward, 30 μL supernatant was added into 200 μL 5 mM ammonium formate containing internal standards at indicated concentrations. Then, all the samples were vortexed for 30 s and centrifuged at 15,000 rpm, 4°C for 5 min again, the final supernatant was used for subsequent measurement. All the samples after handling were immediately analyzed in this study without freezing and thawing.</p><p>The LC-MS/MS system consisted of a triple quadrupole LCMS-8050 (Shimadzu) and an LC-30A system (Shimadzu). NAD<sup>+</sup>, NMN, and the <italic>N</italic>-cyclohexyl benzamide (NCB, internal standard, 5 ng/mL) were eluted on Altlantis HILIC Silica (2.1×150 mm, 5 μm) at 40°C using an isocratic mobile phase containing 60% water with 0.1% formic acid and 40% acetonitrile with 0.1% formic acid at 0.4 mL/min. The selected transitions of m/z were 664.10 → 136.10 for NAD<sup>+</sup>, 334.95 → 123.15 for NMN, and 204.10 → 122.20 for NCB in positive ion mode. NAD<sup>+</sup> and NMN were measured independently in this study, as their peaks were hardly separated within a short time.</p><p>sUA, cADPR, and FYU-981 (internal standard, 1 μM, Fuji Yakuhin Co., Ltd.) were eluted on CAPCELL PAK C8 TYPE UG 120 (2×150 mm, 5 μm) at 40°C. sUA and FYU-981 were separated using a gradient mobile phase containing water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B) at 0.4 mL/min. The elution was started with 55% A for 0.5 min, A was decreased from 55% to 5% for 1 min, then A was increased from 5% to 55% for 0.5 min, finally 55% A was maintained for 0.5 min. cADPR and FYU-981 were separated using an isocratic mobile phase containing 60% water with 0.1% formic acid and 40% acetonitrile with 0.1% formic acid at 0.4 mL/min. The selected transitions of m/z were 167.10 → 124.10 for sUA, 539.95 → 272.95 for cADPR, and 355.95 → 159.90 for FYU-981 in negative ion mode.</p><p>The injection volume was 1 μL for all measurements, and data manipulation was accomplished by Labsolutions software (Shimadzu).</p></sec><sec id="s4-20"><title>Statistical analysis</title><p>Statistics were performed using GraphPad Prism 9. Sample size was not predetermined by any statistical methods. Comparisons between multiple groups were performed using one-way ANOVA with Dunnett’s or Tukey’s multiple comparisons test, Kruskal-Wallis test, Brown-Forsythe and Welch ANOVA tests, or two-way ANOVA with Tukey’s multiple comparisons test. Two-tailed unpaired t-test (with Welch’s correction when applicable), or Mann-Whitney test were used for the analysis between two groups when applicable. Data were shown as mean ± s.e.m. or mean ± s.d. as indicated. p&lt;0.05 was considered significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were approved by the Institutional Animal Care and Use Committee at Kanazawa University (AP-214243).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Comparison between K<sub>i</sub> values and mean levels of soluble uric acid (sUA) in different tissues.</title></caption><media xlink:href="elife-96962-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>The data not shown in enzyme assays.</title></caption><media xlink:href="elife-96962-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>The raw images of chemical structures.</title></caption><media xlink:href="elife-96962-supp3-v1.pptx" mimetype="application" mime-subtype="pptx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-96962-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>No datasets or code are created or reused in this study. All data generated or analyzed in this study are provided in the manuscript text, figures, and supplementary files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This study was supported by KAKENHI (JP21H02641) (IT), (JP23K18181) (IT), and (JP22K19372) (HA) from the Japan Society for the Promotion of Science (JSPS) and Research Grant 2022 (IT) from Gout and Uric Acid Foundation of Japan. SW was funded by the Japanese Government (Monbukagakusho: MEXT) Scholarship Program and Kanazawa University. The authors thank Dr. Zheng Jing, Ms. Aimi Taniguchi, Dr. Anpei Zhang, Mr. Kazuki Himi, and Mr. Kazuki Fujita for providing assistance.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alabarse</surname><given-names>PG</given-names></name><name><surname>Oliveira</surname><given-names>P</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Migaud</surname><given-names>M</given-names></name><name><surname>Terkeltaub</surname><given-names>R</given-names></name><name><surname>Liu-Bryan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>The NADase CD38 is a central regulator in gouty inflammation and a novel druggable therapeutic target</article-title><source>Inflammation Research</source><volume>73</volume><fpage>739</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1007/s00011-024-01863-y</pub-id><pub-id pub-id-type="pmid">38493256</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>BM</given-names></name><name><surname>Barber</surname><given-names>JS</given-names></name><name><surname>Sacre</surname><given-names>SM</given-names></name><name><surname>Davies</surname><given-names>KA</given-names></name><name><surname>Ghezzi</surname><given-names>P</given-names></name><name><surname>Mullen</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Precipitation of soluble uric acid is necessary for In Vitro Activation of the nlrp3 inflammasome in primary human monocytes</article-title><source>The Journal of Rheumatology</source><volume>46</volume><fpage>1141</fpage><lpage>1150</lpage><pub-id pub-id-type="doi">10.3899/jrheum.180855</pub-id><pub-id pub-id-type="pmid">30824640</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Álvarez-Lario</surname><given-names>B</given-names></name><name><surname>Macarrón-Vicente</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Uric acid and evolution</article-title><source>Rheumatology</source><volume>49</volume><fpage>2010</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/keq204</pub-id><pub-id pub-id-type="pmid">20627967</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ames</surname><given-names>BN</given-names></name><name><surname>Cathcart</surname><given-names>R</given-names></name><name><surname>Schwiers</surname><given-names>E</given-names></name><name><surname>Hochstein</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis</article-title><source>PNAS</source><volume>78</volume><fpage>6858</fpage><lpage>6862</lpage><pub-id pub-id-type="doi">10.1073/pnas.78.11.6858</pub-id><pub-id pub-id-type="pmid">6947260</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>MA</given-names></name><name><surname>Schumacher</surname><given-names>HR</given-names><suffix>Jr</suffix></name><name><surname>Wortmann</surname><given-names>RL</given-names></name><name><surname>MacDonald</surname><given-names>PA</given-names></name><name><surname>Eustace</surname><given-names>D</given-names></name><name><surname>Palo</surname><given-names>WA</given-names></name><name><surname>Streit</surname><given-names>J</given-names></name><name><surname>Joseph-Ridge</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Febuxostat compared with allopurinol in patients with hyperuricemia and gout</article-title><source>The New England Journal of Medicine</source><volume>353</volume><fpage>2450</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050373</pub-id><pub-id pub-id-type="pmid">16339094</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blacher</surname><given-names>E</given-names></name><name><surname>Dadali</surname><given-names>T</given-names></name><name><surname>Bespalko</surname><given-names>A</given-names></name><name><surname>Haupenthal</surname><given-names>VJ</given-names></name><name><surname>Grimm</surname><given-names>MOW</given-names></name><name><surname>Hartmann</surname><given-names>T</given-names></name><name><surname>Lund</surname><given-names>FE</given-names></name><name><surname>Stein</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alzheimer’s disease pathology is attenuated in a CD38-deficient mouse model</article-title><source>Annals of Neurology</source><volume>78</volume><fpage>88</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1002/ana.24425</pub-id><pub-id pub-id-type="pmid">25893674</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulieu</surname><given-names>R</given-names></name><name><surname>Bory</surname><given-names>C</given-names></name><name><surname>Baltassat</surname><given-names>P</given-names></name><name><surname>Gonnet</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Hypoxanthine and xanthine levels determined by high-performance liquid chromatography in plasma, erythrocyte, and urine samples from healthy subjects: the problem of hypoxanthine level evolution as a function of time</article-title><source>Analytical Biochemistry</source><volume>129</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/0003-2697(83)90568-7</pub-id><pub-id pub-id-type="pmid">6846839</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho-Pereira</surname><given-names>J</given-names></name><name><surname>Tarragó</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Nin</surname><given-names>V</given-names></name><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Puranik</surname><given-names>AS</given-names></name><name><surname>Schoon</surname><given-names>RA</given-names></name><name><surname>Reid</surname><given-names>JM</given-names></name><name><surname>Galina</surname><given-names>A</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CD38 dictates age-related nad decline and mitochondrial dysfunction through an sirt3-dependent mechanism</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>1127</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.05.006</pub-id><pub-id pub-id-type="pmid">27304511</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantor</surname><given-names>JR</given-names></name><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Kanarek</surname><given-names>N</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Louissaint</surname><given-names>A</given-names><suffix>Jr</suffix></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of ump synthase</article-title><source>Cell</source><volume>169</volume><fpage>258</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.03.023</pub-id><pub-id pub-id-type="pmid">28388410</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name><name><surname>de Toledo</surname><given-names>FG</given-names></name><name><surname>Thompson</surname><given-names>MA</given-names></name><name><surname>Dousa</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Effect of estrogen upon cyclic ADP ribose metabolism: beta-estradiol stimulates ADP ribosyl cyclase in rat uterus</article-title><source>PNAS</source><volume>94</volume><fpage>5872</fpage><lpage>5876</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.11.5872</pub-id><pub-id pub-id-type="pmid">9159167</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>EN</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Espindola Netto</surname><given-names>JM</given-names></name><name><surname>de Oliveira</surname><given-names>GC</given-names></name><name><surname>van Schooten</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The pharmacology of cd38/nadase: an emerging target in cancer and diseases of aging</article-title><source>Trends in Pharmacological Sciences</source><volume>39</volume><fpage>424</fpage><lpage>436</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2018.02.001</pub-id><pub-id pub-id-type="pmid">29482842</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Peclat</surname><given-names>TR</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Kashyap</surname><given-names>S</given-names></name><name><surname>Espindola-Netto</surname><given-names>JM</given-names></name><name><surname>de Oliveira</surname><given-names>GC</given-names></name><name><surname>Gomez</surname><given-names>LS</given-names></name><name><surname>Hogan</surname><given-names>KA</given-names></name><name><surname>Tarragó</surname><given-names>MG</given-names></name><name><surname>Puranik</surname><given-names>AS</given-names></name><name><surname>Agorrody</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>KL</given-names></name><name><surname>Dang</surname><given-names>K</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Childs</surname><given-names>BG</given-names></name><name><surname>Kanamori</surname><given-names>KS</given-names></name><name><surname>Witte</surname><given-names>MA</given-names></name><name><surname>Vidal</surname><given-names>P</given-names></name><name><surname>Kirkland</surname><given-names>AL</given-names></name><name><surname>De Cecco</surname><given-names>M</given-names></name><name><surname>Chellappa</surname><given-names>K</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><name><surname>Jankowski</surname><given-names>C</given-names></name><name><surname>Tchkonia</surname><given-names>T</given-names></name><name><surname>Kirkland</surname><given-names>JL</given-names></name><name><surname>Sedivy</surname><given-names>JM</given-names></name><name><surname>van Deursen</surname><given-names>JM</given-names></name><name><surname>Baker</surname><given-names>DJ</given-names></name><name><surname>van Schooten</surname><given-names>W</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Baur</surname><given-names>JA</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD<sup>+</sup> and NMN levels</article-title><source>Nature Metabolism</source><volume>2</volume><fpage>1284</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1038/s42255-020-00298-z</pub-id><pub-id pub-id-type="pmid">33199925</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawley</surname><given-names>WT</given-names></name><name><surname>Jungels</surname><given-names>CG</given-names></name><name><surname>Stenmark</surname><given-names>KR</given-names></name><name><surname>Fini</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia</article-title><source>Redox Biology</source><volume>51</volume><elocation-id>102271</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2022.102271</pub-id><pub-id pub-id-type="pmid">35228125</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutler</surname><given-names>RG</given-names></name><name><surname>Camandola</surname><given-names>S</given-names></name><name><surname>Feldman</surname><given-names>NH</given-names></name><name><surname>Yoon</surname><given-names>JS</given-names></name><name><surname>Haran</surname><given-names>JB</given-names></name><name><surname>Arguelles</surname><given-names>S</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Uric acid enhances longevity and endurance and protects the brain against ischemia</article-title><source>Neurobiology of Aging</source><volume>75</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.10.031</pub-id><pub-id pub-id-type="pmid">30576885</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Gosling</surname><given-names>AL</given-names></name><name><surname>Gaffo</surname><given-names>A</given-names></name><name><surname>Abhishek</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gout</article-title><source>Lancet</source><volume>397</volume><fpage>1843</fpage><lpage>1855</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00569-9</pub-id><pub-id pub-id-type="pmid">33798500</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>GC</given-names></name><name><surname>Kanamori</surname><given-names>KS</given-names></name><name><surname>Auxiliadora-Martins</surname><given-names>M</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Measuring CD38 hydrolase and cyclase activities: 1,N<sup>6</sup>-ethenonicotinamide adenine dinucleotide (ε-NAD) and nicotinamide guanine dinucleotide (NGD) fluorescence-based methods</article-title><source>Bio-Protocol</source><volume>8</volume><elocation-id>e2938</elocation-id><pub-id pub-id-type="doi">10.21769/BioProtoc.2938</pub-id><pub-id pub-id-type="pmid">30112426</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Morra</surname><given-names>M</given-names></name><name><surname>Mallone</surname><given-names>R</given-names></name><name><surname>Ausiello</surname><given-names>CM</given-names></name><name><surname>Prager</surname><given-names>E</given-names></name><name><surname>Garbarino</surname><given-names>G</given-names></name><name><surname>Dianzani</surname><given-names>U</given-names></name><name><surname>Stockinger</surname><given-names>H</given-names></name><name><surname>Malavasi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member</article-title><source>Journal of Immunology</source><volume>160</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">9551996</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Aydin</surname><given-names>S</given-names></name><name><surname>Grand</surname><given-names>MM</given-names></name><name><surname>Vaisitti</surname><given-names>T</given-names></name><name><surname>Bergui</surname><given-names>L</given-names></name><name><surname>D’Arena</surname><given-names>G</given-names></name><name><surname>Chiorino</surname><given-names>G</given-names></name><name><surname>Malavasi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells</article-title><source>Molecular Medicine</source><volume>16</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.2119/molmed.2009.00146</pub-id><pub-id pub-id-type="pmid">19956559</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehlin</surname><given-names>M</given-names></name><name><surname>Jacobsson</surname><given-names>L</given-names></name><name><surname>Roddy</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors</article-title><source>Nature Reviews. Rheumatology</source><volume>16</volume><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/s41584-020-0441-1</pub-id><pub-id pub-id-type="pmid">32541923</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogan</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>TA</given-names></name><name><surname>Deshpande</surname><given-names>DA</given-names></name><name><surname>Murtaugh</surname><given-names>MP</given-names></name><name><surname>Walseth</surname><given-names>TF</given-names></name><name><surname>Kannan</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Estrogen increases CD38 gene expression and leads to differential regulation of adenosine diphosphate (ADP)-ribosyl cyclase and cyclic ADP-ribose hydrolase activities in rat myometrium</article-title><source>Biology of Reproduction</source><volume>66</volume><fpage>596</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1095/biolreprod66.3.596</pub-id><pub-id pub-id-type="pmid">11870063</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dudzinska</surname><given-names>W</given-names></name><name><surname>Lubkowska</surname><given-names>A</given-names></name><name><surname>Dolegowska</surname><given-names>B</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Jakubowska</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Adenine, guanine and pyridine nucleotides in blood during physical exercise and restitution in healthy subjects</article-title><source>European Journal of Applied Physiology</source><volume>110</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1007/s00421-010-1611-7</pub-id><pub-id pub-id-type="pmid">20714766</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eells</surname><given-names>JT</given-names></name><name><surname>Spector</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fluid and plasma</article-title><source>Neurochemical Research</source><volume>8</volume><fpage>1451</fpage><lpage>1457</lpage><pub-id pub-id-type="doi">10.1007/BF00965000</pub-id><pub-id pub-id-type="pmid">6656991</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escande</surname><given-names>C</given-names></name><name><surname>Nin</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>NL</given-names></name><name><surname>Capellini</surname><given-names>V</given-names></name><name><surname>Gomes</surname><given-names>AP</given-names></name><name><surname>Barbosa</surname><given-names>MT</given-names></name><name><surname>O’Neil</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>TA</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome</article-title><source>Diabetes</source><volume>62</volume><fpage>1084</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.2337/db12-1139</pub-id><pub-id pub-id-type="pmid">23172919</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridovich</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1965">1965</year><article-title>The competitive inhibition of uricase by oxonate and by related derivatives of s-triazines</article-title><source>The Journal of Biological Chemistry</source><volume>240</volume><fpage>2491</fpage><lpage>2494</lpage><pub-id pub-id-type="pmid">14304858</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funaro</surname><given-names>A</given-names></name><name><surname>Horenstein</surname><given-names>AL</given-names></name><name><surname>Calosso</surname><given-names>L</given-names></name><name><surname>Morra</surname><given-names>M</given-names></name><name><surname>Tarocco</surname><given-names>RP</given-names></name><name><surname>Franco</surname><given-names>L</given-names></name><name><surname>De Flora</surname><given-names>A</given-names></name><name><surname>Malavasi</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids</article-title><source>International Immunology</source><volume>8</volume><fpage>1643</fpage><lpage>1650</lpage><pub-id pub-id-type="doi">10.1093/intimm/8.11.1643</pub-id><pub-id pub-id-type="pmid">8943558</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glantzounis</surname><given-names>GK</given-names></name><name><surname>Tsimoyiannis</surname><given-names>EC</given-names></name><name><surname>Kappas</surname><given-names>AM</given-names></name><name><surname>Galaris</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Uric acid and oxidative stress</article-title><source>Current Pharmaceutical Design</source><volume>11</volume><fpage>4145</fpage><lpage>4151</lpage><pub-id pub-id-type="doi">10.2174/138161205774913255</pub-id><pub-id pub-id-type="pmid">16375736</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez</surname><given-names>G</given-names></name><name><surname>Sitkovsky</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo</article-title><source>Blood</source><volume>102</volume><fpage>4472</fpage><lpage>4478</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-11-3624</pub-id><pub-id pub-id-type="pmid">12947007</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haberman</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>S-C</given-names></name><name><surname>Arumugam</surname><given-names>TV</given-names></name><name><surname>Hyun</surname><given-names>D-H</given-names></name><name><surname>Yu</surname><given-names>Q-S</given-names></name><name><surname>Cutler</surname><given-names>RG</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Holloway</surname><given-names>HW</given-names></name><name><surname>Greig</surname><given-names>NH</given-names></name><name><surname>Mattson</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Soluble neuroprotective antioxidant uric acid analogs ameliorate ischemic brain injury in mice</article-title><source>Neuromolecular Medicine</source><volume>9</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1007/s12017-007-8010-1</pub-id><pub-id pub-id-type="pmid">17999205</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hara-Yokoyama</surname><given-names>M</given-names></name><name><surname>Kukimoto</surname><given-names>I</given-names></name><name><surname>Nishina</surname><given-names>H</given-names></name><name><surname>Kontani</surname><given-names>K</given-names></name><name><surname>Hirabayashi</surname><given-names>Y</given-names></name><name><surname>Irie</surname><given-names>F</given-names></name><name><surname>Sugiya</surname><given-names>H</given-names></name><name><surname>Furuyama</surname><given-names>S</given-names></name><name><surname>Katada</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Inhibition of NAD+ glycohydrolase and ADP-ribosyl cyclase activities of leukocyte cell surface antigen CD38 by gangliosides</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>12951</fpage><lpage>12955</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.22.12951</pub-id><pub-id pub-id-type="pmid">8662799</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>H-H</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Qiao</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>M</given-names></name><name><surname>Ohkubo</surname><given-names>R</given-names></name><name><surname>Mu</surname><given-names>W-C</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An acetylation switch of the nlrp3 inflammasome regulates aging-associated chronic inflammation and insulin resistance</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>580</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.01.009</pub-id><pub-id pub-id-type="pmid">32032542</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashida</surname><given-names>H</given-names></name><name><surname>Egorova</surname><given-names>A</given-names></name><name><surname>Higashida</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>ZG</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Sympathetic potentiation of cyclic ADP-ribose formation in rat cardiac myocytes</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>33348</fpage><lpage>33354</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.47.33348</pub-id><pub-id pub-id-type="pmid">10559213</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>KA</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The multi-faceted ecto-enzyme CD38: Roles in immunomodulation, cancer, aging, and metabolic diseases</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1187</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01187</pub-id><pub-id pub-id-type="pmid">31214171</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooftman</surname><given-names>A</given-names></name><name><surname>Angiari</surname><given-names>S</given-names></name><name><surname>Hester</surname><given-names>S</given-names></name><name><surname>Corcoran</surname><given-names>SE</given-names></name><name><surname>Runtsch</surname><given-names>MC</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Ruzek</surname><given-names>MC</given-names></name><name><surname>Slivka</surname><given-names>PF</given-names></name><name><surname>McGettrick</surname><given-names>AF</given-names></name><name><surname>Banahan</surname><given-names>K</given-names></name><name><surname>Hughes</surname><given-names>MM</given-names></name><name><surname>Irvine</surname><given-names>AD</given-names></name><name><surname>Fischer</surname><given-names>R</given-names></name><name><surname>O’Neill</surname><given-names>LAJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>468</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.07.016</pub-id><pub-id pub-id-type="pmid">32791101</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howles</surname><given-names>SA</given-names></name><name><surname>Thakker</surname><given-names>RV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genetics of kidney stone disease</article-title><source>Nature Reviews. Urology</source><volume>17</volume><fpage>407</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/s41585-020-0332-x</pub-id><pub-id pub-id-type="pmid">32533118</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichinose</surname><given-names>W</given-names></name><name><surname>Cherepanov</surname><given-names>SM</given-names></name><name><surname>Shabalova</surname><given-names>AA</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Yuhi</surname><given-names>T</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Watanabe</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>Y</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Horike</surname><given-names>S</given-names></name><name><surname>Terakawa</surname><given-names>J</given-names></name><name><surname>Daikoku</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Mano</surname><given-names>N</given-names></name><name><surname>Higashida</surname><given-names>H</given-names></name><name><surname>Shuto</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Development of a highly potent analogue and a long-acting analogue of oxytocin for the treatment of social impairment-like behaviors</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>3297</fpage><lpage>3310</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01691</pub-id><pub-id pub-id-type="pmid">30896946</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ives</surname><given-names>A</given-names></name><name><surname>Nomura</surname><given-names>J</given-names></name><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Roger</surname><given-names>T</given-names></name><name><surname>LeRoy</surname><given-names>D</given-names></name><name><surname>Miner</surname><given-names>JN</given-names></name><name><surname>Simon</surname><given-names>G</given-names></name><name><surname>Busso</surname><given-names>N</given-names></name><name><surname>So</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Xanthine oxidoreductase regulates macrophage IL1β secretion upon NLRP3 inflammasome activation</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6555</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7555</pub-id><pub-id pub-id-type="pmid">25800347</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwama</surname><given-names>M</given-names></name><name><surname>Kondo</surname><given-names>Y</given-names></name><name><surname>Shimokado</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>N</given-names></name><name><surname>Ishigami</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Uric acid levels in tissues and plasma of mice during aging</article-title><source>Biological &amp; Pharmaceutical Bulletin</source><volume>35</volume><fpage>1367</fpage><lpage>1370</lpage><pub-id pub-id-type="doi">10.1248/bpb.b12-00198</pub-id><pub-id pub-id-type="pmid">22863939</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>H-X</given-names></name><name><surname>Hirai</surname><given-names>H</given-names></name><name><surname>Torashima</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>T</given-names></name><name><surname>Lopatina</surname><given-names>O</given-names></name><name><surname>Shnayder</surname><given-names>NA</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Seike</surname><given-names>T</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Takasawa</surname><given-names>S</given-names></name><name><surname>Yokoyama</surname><given-names>S</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Shiraishi</surname><given-names>Y</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Hashii</surname><given-names>M</given-names></name><name><surname>Yoshihara</surname><given-names>T</given-names></name><name><surname>Higashida</surname><given-names>K</given-names></name><name><surname>Islam</surname><given-names>MS</given-names></name><name><surname>Yamada</surname><given-names>N</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>I</given-names></name><name><surname>Okamoto</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>A</given-names></name><name><surname>Salmina</surname><given-names>A</given-names></name><name><surname>Munesue</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><name><surname>Mochida</surname><given-names>S</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Higashida</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>CD38 is critical for social behaviour by regulating oxytocin secretion</article-title><source>Nature</source><volume>446</volume><fpage>41</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1038/nature05526</pub-id><pub-id pub-id-type="pmid">17287729</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kono</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name><name><surname>Ontiveros</surname><given-names>F</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Uric acid promotes an acute inflammatory response to sterile cell death in mice</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>1939</fpage><lpage>1949</lpage><pub-id pub-id-type="doi">10.1172/JCI40124</pub-id><pub-id pub-id-type="pmid">20501947</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutzing</surname><given-names>MK</given-names></name><name><surname>Firestein</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Altered uric acid levels and disease states</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>324</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1124/jpet.107.129031</pub-id><pub-id pub-id-type="pmid">17890445</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuwabara</surname><given-names>M</given-names></name><name><surname>Niwa</surname><given-names>K</given-names></name><name><surname>Ohtahara</surname><given-names>A</given-names></name><name><surname>Hamada</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>S</given-names></name><name><surname>Mizuta</surname><given-names>E</given-names></name><name><surname>Ogino</surname><given-names>K</given-names></name><name><surname>Hisatome</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Prevalence and complications of hypouricemia in A general population: A large-scale cross-sectional study in Japan</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0176055</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0176055</pub-id><pub-id pub-id-type="pmid">28448596</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzuya</surname><given-names>M</given-names></name><name><surname>Ando</surname><given-names>F</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Shimokata</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group</article-title><source>The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences</source><volume>57</volume><elocation-id>M660</elocation-id><pub-id pub-id-type="doi">10.1093/gerona/57.10.m660</pub-id><pub-id pub-id-type="pmid">12242321</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>J-H</given-names></name><name><surname>Luo</surname><given-names>S-F</given-names></name><name><surname>Hung</surname><given-names>L-F</given-names></name><name><surname>Huang</surname><given-names>C-Y</given-names></name><name><surname>Lien</surname><given-names>S-B</given-names></name><name><surname>Lin</surname><given-names>L-C</given-names></name><name><surname>Liu</surname><given-names>F-C</given-names></name><name><surname>Yen</surname><given-names>BL</given-names></name><name><surname>Ho</surname><given-names>L-J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>2359</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-02640-0</pub-id><pub-id pub-id-type="pmid">28539647</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Walseth</surname><given-names>TF</given-names></name><name><surname>Bratt</surname><given-names>GT</given-names></name><name><surname>Hayes</surname><given-names>RN</given-names></name><name><surname>Clapper</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Structural determination of a cyclic metabolite of NAD+ with intracellular Ca2+-mobilizing activity</article-title><source>The Journal of Biological Chemistry</source><volume>264</volume><fpage>1608</fpage><lpage>1615</lpage><pub-id pub-id-type="pmid">2912976</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers</article-title><source>Annual Review of Pharmacology and Toxicology</source><volume>41</volume><fpage>317</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.41.1.317</pub-id><pub-id pub-id-type="pmid">11264460</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Zhao</surname><given-names>YJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Resolving the topological enigma in Ca<sup>2+</sup> signaling by cyclic ADP-ribose and NAADP</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>19831</fpage><lpage>19843</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV119.009635</pub-id><pub-id pub-id-type="pmid">31672920</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linnerz</surname><given-names>T</given-names></name><name><surname>Sung</surname><given-names>YJ</given-names></name><name><surname>Rolland</surname><given-names>L</given-names></name><name><surname>Astin</surname><given-names>JW</given-names></name><name><surname>Dalbeth</surname><given-names>N</given-names></name><name><surname>Hall</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Uricase-deficient larval zebrafish with elevated urate levels demonstrate suppressed acute inflammatory response to monosodium urate crystals and prolonged crystal persistence</article-title><source>Genes</source><volume>13</volume><elocation-id>2179</elocation-id><pub-id pub-id-type="doi">10.3390/genes13122179</pub-id><pub-id pub-id-type="pmid">36553446</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Logan</surname><given-names>JA</given-names></name><name><surname>Morrison</surname><given-names>E</given-names></name><name><surname>McGill</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Serum uric acid in acute gout</article-title><source>Annals of the Rheumatic Diseases</source><volume>56</volume><fpage>696</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1136/ard.56.11.696a</pub-id><pub-id pub-id-type="pmid">9462177</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomenick</surname><given-names>B</given-names></name><name><surname>Hao</surname><given-names>R</given-names></name><name><surname>Jonai</surname><given-names>N</given-names></name><name><surname>Chin</surname><given-names>RM</given-names></name><name><surname>Aghajan</surname><given-names>M</given-names></name><name><surname>Warburton</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>RP</given-names></name><name><surname>Gomez</surname><given-names>F</given-names></name><name><surname>Loo</surname><given-names>JA</given-names></name><name><surname>Wohlschlegel</surname><given-names>JA</given-names></name><name><surname>Vondriska</surname><given-names>TM</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Herschman</surname><given-names>HR</given-names></name><name><surname>Clardy</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>CF</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Target identification using drug affinity responsive target stability (DARTS)</article-title><source>PNAS</source><volume>106</volume><fpage>21984</fpage><lpage>21989</lpage><pub-id pub-id-type="doi">10.1073/pnas.0910040106</pub-id><pub-id pub-id-type="pmid">19995983</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowell</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hyperuricemia reduces neutrophil function</article-title><source>Blood</source><volume>139</volume><fpage>3354</fpage><lpage>3356</lpage><pub-id pub-id-type="doi">10.1182/blood.2022016275</pub-id><pub-id pub-id-type="pmid">35679075</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>N</given-names></name><name><surname>Dubreuil</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><name><surname>Rai</surname><given-names>SK</given-names></name><name><surname>Ascherio</surname><given-names>A</given-names></name><name><surname>Hernán</surname><given-names>MA</given-names></name><name><surname>Choi</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Gout and the risk of Alzheimer’s disease: a population-based, BMI-matched cohort study</article-title><source>Annals of the Rheumatic Diseases</source><volume>75</volume><fpage>547</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206917</pub-id><pub-id pub-id-type="pmid">25739830</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luongo</surname><given-names>TS</given-names></name><name><surname>Eller</surname><given-names>JM</given-names></name><name><surname>Lu</surname><given-names>M-J</given-names></name><name><surname>Niere</surname><given-names>M</given-names></name><name><surname>Raith</surname><given-names>F</given-names></name><name><surname>Perry</surname><given-names>C</given-names></name><name><surname>Bornstein</surname><given-names>MR</given-names></name><name><surname>Oliphint</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><name><surname>Migaud</surname><given-names>ME</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name><name><surname>Johnsson</surname><given-names>K</given-names></name><name><surname>Ziegler</surname><given-names>M</given-names></name><name><surname>Cambronne</surname><given-names>XA</given-names></name><name><surname>Baur</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SLC25A51 is a mammalian mitochondrial NAD+ transporter</article-title><source>Nature</source><volume>588</volume><fpage>174</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2741-7</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Honarpisheh</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Sellmayr</surname><given-names>M</given-names></name><name><surname>Lindenmeyer</surname><given-names>M</given-names></name><name><surname>Böhland</surname><given-names>C</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Anders</surname><given-names>H-J</given-names></name><name><surname>Steiger</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Soluble uric acid is an intrinsic negative regulator of monocyte activation in monosodium urate crystal-induced tissue inflammation</article-title><source>Journal of Immunology</source><volume>205</volume><fpage>789</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000319</pub-id><pub-id pub-id-type="pmid">32561569</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Immler</surname><given-names>R</given-names></name><name><surname>Pruenster</surname><given-names>M</given-names></name><name><surname>Sellmayr</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>von Brunn</surname><given-names>A</given-names></name><name><surname>von Brunn</surname><given-names>B</given-names></name><name><surname>Ehmann</surname><given-names>R</given-names></name><name><surname>Wölfel</surname><given-names>R</given-names></name><name><surname>Napoli</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Böttcher</surname><given-names>RT</given-names></name><name><surname>Sperandio</surname><given-names>M</given-names></name><name><surname>Anders</surname><given-names>H-J</given-names></name><name><surname>Steiger</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Soluble uric acid inhibits β2 integrin-mediated neutrophil recruitment in innate immunity</article-title><source>Blood</source><volume>139</volume><fpage>3402</fpage><lpage>3417</lpage><pub-id pub-id-type="doi">10.1182/blood.2021011234</pub-id><pub-id pub-id-type="pmid">35303071</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez Molina</surname><given-names>D</given-names></name><name><surname>Jafari</surname><given-names>R</given-names></name><name><surname>Ignatushchenko</surname><given-names>M</given-names></name><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Larsson</surname><given-names>EA</given-names></name><name><surname>Dan</surname><given-names>C</given-names></name><name><surname>Sreekumar</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Nordlund</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</article-title><source>Science</source><volume>341</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1233606</pub-id><pub-id pub-id-type="pmid">23828940</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinon</surname><given-names>F</given-names></name><name><surname>Pétrilli</surname><given-names>V</given-names></name><name><surname>Mayor</surname><given-names>A</given-names></name><name><surname>Tardivel</surname><given-names>A</given-names></name><name><surname>Tschopp</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Gout-associated uric acid crystals activate the NALP3 inflammasome</article-title><source>Nature</source><volume>440</volume><fpage>237</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1038/nature04516</pub-id><pub-id pub-id-type="pmid">16407889</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>T</given-names></name><name><surname>Shimon</surname><given-names>D</given-names></name><name><surname>Youssef</surname><given-names>S</given-names></name><name><surname>Yankovitz</surname><given-names>G</given-names></name><name><surname>Tessler</surname><given-names>A</given-names></name><name><surname>Chernobylsky</surname><given-names>T</given-names></name><name><surname>Gaoni-Yogev</surname><given-names>A</given-names></name><name><surname>Perelroizen</surname><given-names>R</given-names></name><name><surname>Budick-Harmelin</surname><given-names>N</given-names></name><name><surname>Steinman</surname><given-names>L</given-names></name><name><surname>Mayo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>NAD<sup>+</sup> metabolism drives astrocyte proinflammatory reprogramming in central nervous system autoimmunity</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2211310119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2211310119</pub-id><pub-id pub-id-type="pmid">35994674</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>KF</given-names></name><name><surname>Yoshida</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>LR</given-names></name><name><surname>Grozio</surname><given-names>A</given-names></name><name><surname>Kubota</surname><given-names>S</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Redpath</surname><given-names>P</given-names></name><name><surname>Migaud</surname><given-names>ME</given-names></name><name><surname>Apte</surname><given-names>RS</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Yoshino</surname><given-names>J</given-names></name><name><surname>Imai</surname><given-names>S-I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>795</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.013</pub-id><pub-id pub-id-type="pmid">28068222</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minhas</surname><given-names>PS</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Moon</surname><given-names>PK</given-names></name><name><surname>Joshi</surname><given-names>AU</given-names></name><name><surname>Dove</surname><given-names>C</given-names></name><name><surname>Mhatre</surname><given-names>S</given-names></name><name><surname>Contrepois</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lee</surname><given-names>BA</given-names></name><name><surname>Coronado</surname><given-names>M</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Snyder</surname><given-names>MP</given-names></name><name><surname>Migaud</surname><given-names>M</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Andreasson</surname><given-names>KI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Macrophage de novo NAD<sup>+</sup> synthesis specifies immune function in aging and inflammation</article-title><source>Nature Immunology</source><volume>20</volume><fpage>50</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0255-3</pub-id><pub-id pub-id-type="pmid">30478397</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misawa</surname><given-names>T</given-names></name><name><surname>Takahama</surname><given-names>M</given-names></name><name><surname>Kozaki</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome</article-title><source>Nature Immunology</source><volume>14</volume><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/ni.2550</pub-id><pub-id pub-id-type="pmid">23502856</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Ockinger</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Byles</surname><given-names>V</given-names></name><name><surname>McColl</surname><given-names>A</given-names></name><name><surname>Hofer</surname><given-names>AM</given-names></name><name><surname>Horng</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Critical role for calcium mobilization in activation of the NLRP3 inflammasome</article-title><source>PNAS</source><volume>109</volume><fpage>11282</fpage><lpage>11287</lpage><pub-id pub-id-type="doi">10.1073/pnas.1117765109</pub-id><pub-id pub-id-type="pmid">22733741</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Inhibition of lipid peroxidation by methylated analogues of uric acid</article-title><source>The Journal of Pharmacy and Pharmacology</source><volume>43</volume><fpage>885</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1991.tb03204.x</pub-id><pub-id pub-id-type="pmid">1687594</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>M</given-names></name><name><surname>Satta</surname><given-names>Y</given-names></name><name><surname>Takenaka</surname><given-names>O</given-names></name><name><surname>Takahata</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Loss of urate oxidase activity in hominoids and its evolutionary implications</article-title><source>Molecular Biology and Evolution</source><volume>19</volume><fpage>640</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.molbev.a004123</pub-id><pub-id pub-id-type="pmid">11961098</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Partida-Sánchez</surname><given-names>S</given-names></name><name><surname>Cockayne</surname><given-names>DA</given-names></name><name><surname>Monard</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>EL</given-names></name><name><surname>Oppenheimer</surname><given-names>N</given-names></name><name><surname>Garvy</surname><given-names>B</given-names></name><name><surname>Kusser</surname><given-names>K</given-names></name><name><surname>Goodrich</surname><given-names>S</given-names></name><name><surname>Howard</surname><given-names>M</given-names></name><name><surname>Harmsen</surname><given-names>A</given-names></name><name><surname>Randall</surname><given-names>TD</given-names></name><name><surname>Lund</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo</article-title><source>Nature Medicine</source><volume>7</volume><fpage>1209</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1038/nm1101-1209</pub-id><pub-id pub-id-type="pmid">11689885</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peclat</surname><given-names>TR</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Varga</surname><given-names>J</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis</article-title><source>Current Opinion in Rheumatology</source><volume>32</volume><fpage>488</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1097/BOR.0000000000000737</pub-id><pub-id pub-id-type="pmid">32941246</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piedra-Quintero</surname><given-names>ZL</given-names></name><name><surname>Wilson</surname><given-names>Z</given-names></name><name><surname>Nava</surname><given-names>P</given-names></name><name><surname>Guerau-de-Arellano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CD38: an immunomodulatory molecule in inflammation and autoimmunity</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>597959</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.597959</pub-id><pub-id pub-id-type="pmid">33329591</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajman</surname><given-names>L</given-names></name><name><surname>Chwalek</surname><given-names>K</given-names></name><name><surname>Sinclair</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Therapeutic potential of NAD-boosting molecules: The in vivo evidence</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>529</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.02.011</pub-id><pub-id pub-id-type="pmid">29514064</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>GS</given-names></name><name><surname>Spitsin</surname><given-names>SV</given-names></name><name><surname>Kean</surname><given-names>RB</given-names></name><name><surname>Mikheeva</surname><given-names>T</given-names></name><name><surname>Koprowski</surname><given-names>H</given-names></name><name><surname>Hooper</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors</article-title><source>PNAS</source><volume>99</volume><fpage>16303</fpage><lpage>16308</lpage><pub-id pub-id-type="doi">10.1073/pnas.212645999</pub-id><pub-id pub-id-type="pmid">12451183</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Evans</surname><given-names>JE</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular identification of a danger signal that alerts the immune system to dying cells</article-title><source>Nature</source><volume>425</volume><fpage>516</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/nature01991</pub-id><pub-id pub-id-type="pmid">14520412</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Caught red-handed: uric acid is an agent of inflammation</article-title><source>The Journal of Clinical Investigation</source><volume>120</volume><fpage>1809</fpage><lpage>1811</lpage><pub-id pub-id-type="doi">10.1172/JCI43132</pub-id><pub-id pub-id-type="pmid">20501951</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarragó</surname><given-names>MG</given-names></name><name><surname>Chini</surname><given-names>CCS</given-names></name><name><surname>Kanamori</surname><given-names>KS</given-names></name><name><surname>Warner</surname><given-names>GM</given-names></name><name><surname>Caride</surname><given-names>A</given-names></name><name><surname>de Oliveira</surname><given-names>GC</given-names></name><name><surname>Rud</surname><given-names>M</given-names></name><name><surname>Samani</surname><given-names>A</given-names></name><name><surname>Hein</surname><given-names>KZ</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Jurk</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>DS</given-names></name><name><surname>Boslett</surname><given-names>JJ</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Zweier</surname><given-names>JL</given-names></name><name><surname>Passos</surname><given-names>JF</given-names></name><name><surname>Doles</surname><given-names>JD</given-names></name><name><surname>Becherer</surname><given-names>DJ</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A potent and specific cd38 inhibitor ameliorates age-related metabolic dysfunction by reversing Tissue NAD<sup>+</sup> Decline</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>1081</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.016</pub-id><pub-id pub-id-type="pmid">29719225</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traut</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Physiological concentrations of purines and pyrimidines</article-title><source>Molecular and Cellular Biochemistry</source><volume>140</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/BF00928361</pub-id><pub-id pub-id-type="pmid">7877593</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urano</surname><given-names>W</given-names></name><name><surname>Yamanaka</surname><given-names>H</given-names></name><name><surname>Tsutani</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Matsuda</surname><given-names>Y</given-names></name><name><surname>Taniguchi</surname><given-names>A</given-names></name><name><surname>Hara</surname><given-names>M</given-names></name><name><surname>Kamatani</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis</article-title><source>The Journal of Rheumatology</source><volume>29</volume><fpage>1950</fpage><lpage>1953</lpage><pub-id pub-id-type="pmid">12233891</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Q-L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Uric acid induces stress resistance and extends the life span through activating the stress response factor DAF-16/FOXO and SKN-1/NRF2</article-title><source>Aging</source><volume>12</volume><fpage>2840</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.18632/aging.102781</pub-id><pub-id pub-id-type="pmid">32074508</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>D-H</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Kanellis</surname><given-names>J</given-names></name><name><surname>Lan</surname><given-names>H</given-names></name><name><surname>Mazzali</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity</article-title><source>Hypertension</source><volume>40</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1161/01.hyp.0000028589.66335.aa</pub-id><pub-id pub-id-type="pmid">12215479</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Tamai</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CD38 activation by monosodium urate crystals contributes to inflammatory responses in human and murine macrophages</article-title><source>Biochemical and Biophysical Research Communications</source><volume>581</volume><fpage>6</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.10.010</pub-id><pub-id pub-id-type="pmid">34637964</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>S</given-names></name><name><surname>Arakawa</surname><given-names>H</given-names></name><name><surname>Tamai</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Uric acid in health and disease: From physiological functions to pathogenic mechanisms</article-title><source>Pharmacology &amp; Therapeutics</source><volume>256</volume><elocation-id>108615</elocation-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2024.108615</pub-id><pub-id pub-id-type="pmid">38382882</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>XW</given-names></name><name><surname>Muzny</surname><given-names>DM</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Caskey</surname><given-names>CT</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Two independent mutational events in the loss of urate oxidase during hominoid evolution</article-title><source>Journal of Molecular Evolution</source><volume>34</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/BF00163854</pub-id><pub-id pub-id-type="pmid">1556746</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>CD38 Inhibition Attenuates Monosodium Urate Crystal-Induced Inflammation in Macrophages</source><publisher-loc>San Diego</publisher-loc><publisher-name>University of California</publisher-name></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeidler</surname><given-names>JD</given-names></name><name><surname>Kashyap</surname><given-names>S</given-names></name><name><surname>Hogan</surname><given-names>KA</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Implications of the NADase CD38 in COVID pathophysiology</article-title><source>Physiological Reviews</source><volume>102</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1152/physrev.00007.2021</pub-id><pub-id pub-id-type="pmid">34494892</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>YJ</given-names></name><name><surname>Lam</surname><given-names>CMC</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The membrane-bound enzyme CD38 exists in two opposing orientations</article-title><source>Science Signaling</source><volume>5</volume><elocation-id>ra67</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2002700</pub-id><pub-id pub-id-type="pmid">22969159</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielinska</surname><given-names>W</given-names></name><name><surname>Barata</surname><given-names>H</given-names></name><name><surname>Chini</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Metabolism of cyclic ADP-ribose: Zinc is an endogenous modulator of the cyclase/NAD glycohydrolase ratio of a CD38-like enzyme from human seminal fluid</article-title><source>Life Sciences</source><volume>74</volume><fpage>1781</fpage><lpage>1790</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2003.08.033</pub-id><pub-id pub-id-type="pmid">14741735</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96962.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Marcelo A</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>State University of Campinas</institution><country>Brazil</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study shows that soluble uric acid is an endogenous inhibitor of CD38, a regulator of inflammatory responses. The <bold>convincing</bold> evidence draws both on biochemical analyses and in vivo models. This work provides insights into NAD+ metabolism, with significant implications for inflammation and potential roles in metabolic diseases and aging.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96962.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>This manuscript describes soluble Uric Acid (sUA) as an endogenous inhibitor of CD38, affecting CD38 activity and NAD+ levels both in vitro and in vivo. Importantly, the inhibition constants calculated supports the claim that sUA inhibits CD38 under physiological conditions. These findings are of extreme importance to understand the regulation of an enzyme that has been shown to be the main NAD+/NMN-degrading enzyme in mammals, which impacts several metabolic processes and has major implications to understanding aging diseases. The manuscript is well written, the figures are self explanatory, and in the experiments presented, the data is very solid. The authors discuss the main limitations of the study, especially in regard to the in vivo results. As a whole, I believe that this is a very interesting manuscript that will be appreciated by the scientific community and that opens a lot of new questions in the field of metabolism and aging.</p><p>During the revision process, the authors have performed new experiments to respond to relevant questions raised by the reviewers. In other cases, they have made changes in the text to improve the manuscript.</p><p>I believe that this manuscript in its current form is a mature and relevant set of findings that deserve attention and future developments.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96962.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This is an interesting work where Wen et al. aimed to shed light on the mechanisms driving the protective role of soluble uric acid (sUA) toward avoiding excessive inflammation. They present biochemical data to support that sUA inhibits the enzymatic activity of CD38 (Figures 1 and 2). In a mouse model of acute response to sUA and using mice deficient in CD38, they find evidence that sUA increases the plasma levels of nicotinamide nucleotides (NAD+ and NMN) (Figure 3) and that sUA reduces the plasma levels of inflammasome-driven cytokines IL-1b and IL-18 in response to endotoxin, both dependent on CD38 (Figure 4). Their work is an important advance in the understanding of the physiological role of sUA, with mechanistic insight that can have important clinical implications.</p><p>Strengths:</p><p>The authors present evidence from different approaches to support that sUA inhibits CD38, impacts NAD+ levels, and regulates inflammatory responses through CD38.</p><p>Weaknesses:</p><p>The authors investigate macrophages as the cells affected by sUA in promoting immunoregulation, proposing that sUA's inhibition of CD38 and the resulting increase in NAD+ promotes inflammasome inhibition through a previously established mechanism of NLRP3 regulation by NAD+-dependent sirtuins. However, they were unable to validate their in vivo findings using murine bone marrow-derived macrophages, a standard model for assessing inflammasome activation, due to the low uptake of sUA in these cells. Pharmacological blockage in THP-1 cells provides mechanistic evidence that sUA inhibits NLRP3-mediated secretion of IL-1β through CD38, but genetic evidence and direct assessment of the activation of inflammasome components would be necessary to fully validate the model.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96962.3.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>In the present manuscript, the authors propose that soluble Uric acid (sUA) is an enzymatic inhibitor of the NADase CD38 and that it controls levels of NAD modulating inflammatory response. Although interesting the studies are at this stage preliminary and validation is needed.</p><p>Strengths:</p><p>The study characterizes the potential relevance of sUA in NAD metabolism.</p><p>Comment on revised version:</p><p>The authors have responded the majority of my criticism.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.96962.3.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Shijie</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Arakawa</surname><given-names>Hiroshi</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Yokoyama</surname><given-names>Shigeru</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Shirasaka</surname><given-names>Yoshiyuki</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Higashida</surname><given-names>Haruhiro</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Tamai</surname><given-names>Ikumi</given-names></name><role specific-use="author">Author</role><aff><institution>Kanazawa University</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>This manuscript describes soluble Uric Acid (sUA) as an endogenous inhibitor of CD38, affecting CD38 activity and NAD+ levels both in vitro and in vivo. Importantly, the inhibition constants calculated support the claim that sUA inhibits CD38 under physiological conditions. These findings are of extreme importance to understanding the regulation of an enzyme that has been shown to be the main NAD+/NMN-degrading enzyme in mammals, which impacts several metabolic processes and has major implications for understanding aging diseases. The manuscript is well written, the figures are self-explanatory, and in the experiments presented, the data is very solid. The authors discuss the main limitations of the study, especially in regard to the in vivo results. As a whole, I believe that this is a very interesting manuscript that will be appreciated by the scientific community and that opens a lot of new questions in the field of metabolism and aging. I found some issues that I believe constitute a weakness in the manuscript, and although they do not require new experiments, they may be considered by the authors for discussion in the final version of the manuscript.</p></disp-quote><p>We greatly appreciate the reviewer’s thoughtful comments and favorable review of our work.</p><disp-quote content-type="editor-comment"><p>The authors acknowledge the existence of several previous papers involving pharmacological inhibition of CD38 and their impact on several models of metabolism and aging. However, they only cite reviews. Given the focus of the manuscript, I believe that the seminal original papers should be cited.</p></disp-quote><p>Yes, we agreed with the reviewer. Two representative papers regarding the pioneering findings [Ref 1, 2] of pharmacological inhibition of CD38 were cited in the discussion of current manuscript.</p><p>(1) Tarragó, M. G., et al. (2018). A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27(5): 1081-1095.e1010.</p><p>(2) Escande, C., et al. (2013). Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62(4): 1084-1093.</p><disp-quote content-type="editor-comment"><p>Related to the previous comment, the authors show that they have identified the functional group on sUA that inhibits CD38, 1,3-dihydroimidazol-2-one. How does this group relate with previous structures that were shown to inhibit CD38 and do not have this chemical structure? Is sUA inhibiting CD38 in a different site? A crystallographic structure of CD38-78c is available in PDB that could be used to study or model these interactions.</p></disp-quote><p>Currently, there are several kinds of CD38 inhibitors, including NAD+/NMN analogs, flavonoids, 4-quinolines, etc. [Ref 1], but they do not have 1,3-dihydroimidazol-2-one or similar groups. We also noticed that sUA and its analogs have no remarkable structural similarity with these inhibitors. We have ever tried to identify the binding sites of sUA on CD38 by NMR. Since our NMR method required a large sample size, we had to prepare recombinant human CD38 using a cell-free protein synthesis system. However, the obtained CD38 protein showed a lower Vmax than commercial recombinant CD38 expressed in HEK293 cells, raising a concern of spatial conformation deference in the synthesized CD38. Thus, we were unable to get convinced data to confirm if sUA has different binding sites. Given the difference in structural feature and inhibition type, we did not use the PDB data regarding 78c-CD38 interaction for analysis in this study.</p><p>(1) Chini, E. N., et al. (2018). The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging. Trends Pharmacol Sci 39(4): 424-436.</p><disp-quote content-type="editor-comment"><p>Although the mouse model used to manipulate sUA levels is not ideal, the authors discuss its limitations, and importantly, they have CD38 KO mice as control. However, all the experiments were performed in very young mice, where CD38 expression is low in most tissues (10.1016/j.cmet.2016.05.006). This point should be mentioned in the discussion and maybe put in the context of variations of sUA levels during aging.</p></disp-quote><p>We appreciate the reviewer’s kind suggestions. Yes, CD38 expression in young mice is relatively low and we used young mice in this study; thus, aged mice would be promising to furthest evaluate the interaction between CD38 and sUA. Regarding the changes in sUA levels during aging, previous reports indicate that sUA levels seem to increase with age in mice and humans [Ref 1, 2]. We speculate that this increase is a physiologically compensatory response to aging in organisms. Accordingly, we added more details in the discussion (second paragraph).</p><p>(1) Iwama, M., et al. (2012). Uric acid levels in tissues and plasma of mice during aging. Biol Pharm Bull 35(8): 1367-1370.</p><p>(2) Kuzuya, M., et al. (2002). Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol A Biol Sci Med Sci 57(10): M660-664.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This is an interesting work where Wen et al. aimed to shed light on the mechanisms driving the protective role of soluble uric acid (sUA) toward avoiding excessive inflammation. They present biochemical data to support that sUA inhibits the enzymatic activity of CD38 (Figures 1 and 2). In a mouse model of acute response to sUA and using mice deficient in CD38, they find evidence that sUA increases the plasma levels of nicotinamide nucleotides (NAD+ and NMN) (Figure 3) and that sUA reduces the plasma levels of inflammasome-driven cytokines IL-1b and IL-18 in response to endotoxin, both dependent on CD38 (Figure 4). Their work is an important advance in the understanding of the physiological role of sUA, with mechanistic insight that can have important clinical implications.</p><p>Strengths:</p><p>The authors present evidence from different approaches to support that sUA inhibits CD38, impacts NAD+ levels, and regulates inflammatory responses through CD38.</p></disp-quote><p>We deeply thank the reviewer for the thoughtful comments and appreciation of our findings.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The authors investigate macrophages as the cells impacted by sUA to promote immunoregulation, proposing that inflammasome inhibition occurs through NAD+ accumulation and sirtuin activity due to sUA inhibition of CD38. Unfortunately, the study still lacks data to support this model, as they could not replicate their in vivo findings using murine bone marrow-derived macrophages, a standard model to assess inflammasome activation. Without an alternative approach, the study lacks data to establish in vitro that sUA inhibition of CD38 reduces inflammasome activation in macrophages - consequently, they cannot determine yet if both NAD+ accumulation and sirtuin activity in macrophages is a mechanism leading to sUA role in vivo.</p></disp-quote><p>We deeply thank the reviewer for pointing out this weakness in our work. In fact, we tried to prepare stable CD38 KD/KO THP-1 cells in the middle of 2021; however, we faced some technical problems due to the limitations of instruments. Thus, we used CD38 KO mice to prepare CD38 KO BMDMs, as shown in the first version of manuscript, we failed to replicate the results in BMDMs because of the low uptake of sUA. To address the reviewer’s concern regarding the lack of an in vitro link between CD38 and sUA immunosuppression, we used 78c, a highly specific and potent inhibitor of CD38, to block CD38 in primed THP-1 cells. Then we evaluated the effect of sUA pre-incubation on MSU crystal-induced IL-1β release in primed THP-1 cells (vehicle and CD38 blockade). The added results in Figure 4-figure supplement 2B and 2C indicated that CD38 blockade largely impaired the immunosuppressive effect of sUA without reducing sUA uptake. In addition, we found that sUA at physiological levels boosted NAD+ levels in THP-1 cells (Figure 3-figure supplement 1B) without affecting the activities of other key enzymes involved in NAD+ synthesis and degradation, including NAMPT and PARP (Figure 3-figure supplement 2). All these results supported that CD38 is a key mediator for sUA at physiological levels to regulate inflammasome activation in vitro.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Public Review):</bold></p><p>Summary:</p><p>In the present manuscript, the authors propose that soluble Uric acid (sUA) is an enzymatic inhibitor of the NADase CD38 and that it controls levels of NAD modulating inflammatory response. Although interesting the studies are at this stage preliminary and validation is needed.</p><p>Strengths:</p><p>The study characterizes the potential relevance of sUA in NAD metabolism.</p></disp-quote><p>We greatly appreciate the reviewer for the thoughtful comments and valuable suggestions.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>(1) A full characterization of the effect of sUA in other NAD-consuming and synthesizing enzymes is needed to validate the statement that the mechanism of regulation of NAD by sUA is mediated by CD38, The CD38 KO may not serve as the ideal control since it may saturate NAD levels already. Analysis of multiple tissues is needed.</p></disp-quote><p>Yes, it is necessary to confirm if sUA affects other NAD+-consuming and synthesizing enzymes. To address the concern and to provide additional validation, we tested the direct effects of sUA and other purine derivates on the activities of another two key enzymes involved in the metabolic network of NAD+, including PARP (NAD+-consuming enzyme) and NAMPT (NAD+-synthesizing enzyme). The added results in Figure 3-figure supplement 2 showed that sUA has no effect on PARP and NAMPT activity, suggesting that CD38 is a main target for sUA in regulating NAD+ availability. In addition, we also confirmed both PARP and NAMPT were not affected by purine metabolism under physiological conditions. Although hypoxanthine and xanthine, at 500 μM (supraphysiological levels), slightly inhibited PARP activity, it has no physiological significance due to their low physiological concentrations (generally below 20 μM). Further evaluation of these inhibitory effects under pathological conditions would be of interest but were beyond the focus of this study.</p><p>Given that tissue sUA uptake is saturated under physiological conditions (tissue sUA did not increase in our models, Figure 3-figure supplement 5A and 5B), CD38 and other potential targets in tissues may be not affected by sUA in our models. We used CD38 KO mice to confirm if sUA interacts with other targets to regulate NAD+ degradation and inflammatory responses. A previous study [Ref 1] revealed that inhibition of other enzymes involved in NAD+ metabolism, such as PARP, resulted in a significant increase of NAD+ availability in CD38 KO mice, which indicates that CD38 KO mice can be used to exclude the potential interaction between sUA and other targets. In fact, we did not observe significant effects of sUA in CD38 KO mice. More importantly, we added the additional validation regarding PARP and NAMPT activity according to the reviewer’s kind suggestion, which further confirmed that CD38 is the main target for sUA in our models.</p><p>(1) Tarragó, M. G., et al. (2018). A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab 27(5): 1081-1095.e1010.</p><disp-quote content-type="editor-comment"><p>(2) The physiological role of sUA as an endogenous inhibitor of CD38 needs stronger validation (sUA deficient model?).</p></disp-quote><p>We thank the reviewer’s insightful suggestions. Yes, sUA depletion model is ideal for further validation, as we discussed in the limitations of this study. Given that introduction of exogenous recombinant uricase (immunometabolism may be affected) to deplete sUA is not ideal for the evaluation under physiological conditions, uricase-transgenic mice would be a promising model. However, now we have no uricase-transgenic mice, and we are unable to prepare CD38 KO/uricase-transgenic mice for additional validation within a reasonable time. In the first version of manuscript, therefore, we used an sUA-release model in sUA-supplementation mice as a further validation in Figure 3E.</p><disp-quote content-type="editor-comment"><p>(3) Flux studies would also be necessary to make the conclusion stronger.</p></disp-quote><p>Answer: We highly appreciate the reviewer’s suggestion regarding metabolic flux analysis. Yes, flux analysis using specifically designed isotope-labeled NAD+ is an ideal validation in mice, as it can track any sUA-induced changes in NAD+ metabolism. However, we are unable to synthesize or obtain suitable isotope-labeled substrates for in vivo validation due to the technical limitations and financial burdens.</p><disp-quote content-type="editor-comment"><p><bold>Recommendations for the authors:</bold></p><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><p>The manuscript is very solid and very well-presented and discussed. In my opinion, the only weakness in the writing is that the message about finding an endogenous regulator of CD38 activity and NAD levels gets blurred by the temptation of jumping into the potential of developing new pharmacological CD38 inhibitors based on sUA structure. My recommendation would be to focus on delivering a clear message about sUA as a physiological inhibitor of CD38, and the possible implications for understanding the onset and evolution of metabolic diseases and aging. Maybe leave the potential of developing novel sUA-based CD38 inhibitors for a final comment. I understand this last point is very attractive, but there are very potent pharmacological CD38 inhibitors already available with promising results.</p></disp-quote><p>We greatly appreciate the reviewer’s valuable suggestions. Yes, there are some promising CD38 inhibitors with nanomolar Ki such as 78c. To clearly focus on sUA as a physiological inhibitor of CD38, we simplified the description in the manuscript and just keep the discussion of functional group. Since the data regarding the development of CD38 inhibitors in our manuscript remain limited, we did not put it in a separate part. We believe the simplified information is still sufficient for medicinal chemists who are interested in the development of CD38 inhibitors.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Major comments:</p><p>(1) The authors present several pieces of data to explain why there is no impact of sUA in inflammasome-mediated cytokine secretion, which is convincing and supports that BMDM will not be a model of choice to establish macrophages as the target of sUA. However, their data with THP-1 cells is compelling and could be further explored using shRNA, or CRISPR approaches to deplete CD38, thus establishing a mechanistic link in vitro.</p></disp-quote><p>We greatly appreciate the reviewer’s thoughtful comments. We added more results as mentioned before (please see our response to public review).</p><disp-quote content-type="editor-comment"><p>(2) There is a severe lack of linearity in how the figures are presented in the main text, making it difficult to read through the manuscript. The figures should be presented in the order they appear in the panels.</p></disp-quote><p>We thank the reviewer for pointing out this issue. We improved the figure assembly according to eLife guidelines.</p><disp-quote content-type="editor-comment"><p>Minor comments:</p><p>(1) The authors do not appropriately address the finding that CD38 impacts the secretion of IL-1b in BMDM (Figure S6B) and in vivo (Figure 4), possibly independently of sUA.</p></disp-quote><p>Yes, the regulatory effect of CD38 on cytokine release seems independent of sUA. In fact, we used CD38 KO BMDMs to validate the role of CD38 in the inflammasome activation. We showed that sUA levels are comparable between WT and KO mice, suggesting that CD38 KO does not affect the baselines and boosted levels of sUA in our models. In this situation, we were able to evaluate the immunosuppressive effects of sUA at the same physiological levels in WT and CD38 KO mice, thus providing evidence to support that sUA at physiological levels limits excessive inflammation via CD38.</p><disp-quote content-type="editor-comment"><p>(2) Figure 3F: the legend on the x-axis lacks the indication of which groups were treated with recombinant hCD38.</p></disp-quote><p>We appreciate the reviewer’s comments. We improved Figure 3 by adding more information.</p><disp-quote content-type="editor-comment"><p>(3) While the results on panels 3 and 4 provide robust evidence that sUA is anti-inflammatory through CD38, the title of the figures extrapolates their findings (i.e., no data shows CD38-sUA, either in vitro or in vivo).</p></disp-quote><p>We appreciate the reviewer’s kind suggestion. We provided data to support the direct interaction between CD38 and sUA in Figure 3F; we admitted that we did not show the data regarding the direct interaction in mice in Figure 4. To help readers easily track the results, however, we used a conclusion-like title.</p><disp-quote content-type="editor-comment"><p>(4) The introduction could briefly mention NMN and CD38 activity as an ecto-enzyme to facilitate the understanding of their findings by a general audience, especially the dosing of NMN and their data on BMDM.</p></disp-quote><p>We added more description regarding CD38 and NMN in the introduction part. Once again, we deeply thank the reviewer for the valuable suggestions.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #3 (Recommendations For The Authors):</bold></p><p>(1) A full characterization of the effect of sUA in other NAD-consuming and synthesizing enzymes is needed to validate the statement that the mechanism of regulation of NAD by sUA is mediated by CD38, The CD38 KO may not serve as the ideal control since it may saturate NAD levels already. Analysis of multiple tissues is needed.</p></disp-quote><p>We greatly appreciate the reviewer’s valuable suggestions. We added more results to validate CD38 as the main target of sUA in our models. Please see our response to public review.</p><disp-quote content-type="editor-comment"><p>(2) The physiological role of sUA as an endogenous inhibitor of CD38 needs stronger validation (sUA deficient model?).</p></disp-quote><p>We greatly appreciate the reviewer’s valuable suggestions. Please see our response to public review.</p><disp-quote content-type="editor-comment"><p>(3) Flux studies would also be necessary to make the conclusion stronger.</p></disp-quote><p>We greatly appreciate the reviewer’s valuable suggestions. Please see our response to public review.</p></body></sub-article></article>